Author index*

A

Abbate R (*see* Michelucci et al). 1999;138:128-32
Abraira C, McGuire DK. Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans Affairs (VA CSDM) feasibility trial. 1999;138:S360-S365
Adams Jr KF (*see* O'Connor et al). 1999;138:78-86
Addad F (*see* Jarrar et al). 1999;138:950-4
Adler AI, Neil HAW, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). 1999;138:S353-S359
Agarrado A (*see* Morales et al). 1999;138:291-8
Agarwal JB (*see* Khaw et al). 1999;138:934-40
Agati L. Microvascular integrity after reperfusion therapy. 1999; 138:S76-S78
Agostini D (*see* Hamon et al). 1999;138:55-9
Agostoni P (*see* Guazzi et al). 1999;138:460-7
Agostoni P (*see* Guazzi et al). 1999;138:254-60
Aguirre FV (*see* Scirica et al). 1999;138:1065-72
Aizawa T (*see* Tamai et al). 1999;138:968-75
Ajluni SC, O'Neill WW. Primary intervention in acute myocardial infarction: do bankers' hours suffice, or should we invest in resources elsewhere? 1999;138:1012-3
Al-Khatib S (*see* Alexander et al). 1999;138:175-90
Al-Khatib SM, Pritchett ELC. Clinical features of Wolff-Parkinson-White syndrome. 1999;138:403-13
Alam M (*see* Ali et al). 1999;138:1133-9
Alcocer MA (*see* Escaned et al). 1999;138:675-80
Alexander JH, Al-Khatib S, Cantor W, Greenbaum AB, Hudson MP, Kong DF, Shah M. Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999. 1999;138:175-90
Alfonso F (*see* Escaned et al). 1999;138:675-80
Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. 1999;138:1133-9
Alivertis M (*see* Halle et al). 1999;138:309-12
Ambrose JA (*see* Dangas et al). 1999;138:49-54
Ambrosio G, Tritto I. Reperfusion injury: experimental evidence and clinical implications. 1999;138:S69-S75
Amende I (*see* Blessing et al). 1999;138:1199 (Letter reply)
Anastasiadis G (*see* Makris et al). 1999;138:922-5
Anderson HV (*see* Scirica et al). 1999;138:1065-72
Anderson JL (*see* Goldstein et al). 1999;138:1158-65
Anstrom KJ, Jollis JG. Translation of clinical evidence into medical practice. 1999;138:1001-2
Antman EM, Cohen M. Newer antithrombin agents in acute coronary syndromes. 1999;138:S563-S569
Antonioli G (*see* Ferrari et al). 1999;138:S61-S68
Antoniucci D, Valenti R, Trapani M, Moschi G. Current role of stenting in acute myocardial infarction. 1999;138:S147-S152
Antoniucci D, Valenti R, Santoro GM, Bolognese L, Moschi G, Trapani M, Taddeucci E, Fazzini PF. Systematic primary angioplasty in octogenarian and older patients. 1999;138: 670-4
Antonucci E (*see* Michelucci et al). 1999;138:128-32
Antwi EA (*see* Vesely et al). 1999;138:625-32

*July, part 1, pp. 1-190; part 2, pp. S1-S46; August, part 1, pp. 191-386; part 2, pp. S47-S202; September, part 1, pp. 387-592; part 2, pp. S203-S260; October, part 1, pp. 593-800; part 2, pp. S261-S326; November, part 1, pp. 801-1000, S327-S416; part 2, pp. S417-S560; December, part 1, pp. 1001-1200; part 2, pp. S561-S594.

Apicella C (*see* Bonaduce et al). 1999;138:273-84
Apple FS, Sharkey SW. Cardiac troponin I as a marker for AMI. 1999;138:798 (Letter reply)
Arbab-Zadeh A, DeMaria AN, Penny WF, Russo RJ, Kimura BJ, Bhargava V. Axial movement of the intravascular ultrasound probe during the cardiac cycle: implications for three-dimensional reconstruction and measurements of coronary dimensions. 1999;138:865-72
Arber N (*see* Kassirer et al). 1999;138:555-9
Arbustini E, Morbini P, Dal Bello B, Prati F, Specchia G. From plaque biology to clinical setting. 1999;138:S55-S60
Ardehali A, Kessler D, Foroushani F, Laks H. Multivessel coronary artery bypass surgery without cardiopulmonary bypass. 1999;138:983-6
Ardissino D (*see* Ferrario et al). 1999;138:S121-S125
Arheart KL (*see* Klein et al). 1999;138:880-9
Armstrong G (*see* Pasquet et al). 1999;138:753-8
Armstrong PW (*see* McAlister et al). 1999;138:87-94
Armstrong WF (*see* Oral et al). 1999;138:364-8
Arnold AM (*see* Gilchrist et al). 1999;138:976-82
Arnold MO (*see* Parker et al). 1999;138:843-8
Arora R (*see* Kalra et al). 1999;138:339-44
Asakawa K (*see* Koyama et al). 1999;138:468-76
Asher CR, Topol EJ, Moliterno DJ. Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes. 1999;138:138:1073-81
Avorn J (*see* Knight et al). 1999;138:849-55
Axel L (*see* Götte et al). 1999;138:1038-45
Aytemir K, Yap YG. Effect of acute ischemia on QT dispersion. 1999;138:385 (Letter)
Azevedo ER (*see* Parker et al). 1999;138:843-8

B

Baardman T (*see* Moons et al). 1999;138:525-32
Babb J (*see* Qamar et al). 1999;138:705-9
Babic UU (*see* Hoepp et al). 1999;138:941-9
Bach DS. (*see* Oral et al). 1999;138:364-8
Badimon JJ (*see* Dangas et al). 1999;138:49-54
Baird MG (*see* Parker et al). 1999;138:843-8
Baker C (*see* Pescatello et al). 1999;138:916-21
Baker DW, Hayes RP, Massie BM, Craig CA. Variations in family physicians' and cardiologists' care for patients with heart failure. 1999;138:826-34
Balazs E (*see* Bhatt et al). 1999;138:785-90
Bañuelos C (*see* Escaned et al). 1999;138:675-80
Bao W (*see* Urbina et al). 1999;138:122-7
Bär FW (*see* Spiecker et al). 1999;138:518-24
Barbash GI (*see* Mahaffey et al). 1999;138;493-9
Barmeyer J (*see* Machraoui et al). 1999;138:663-9
Barriales V (*see* Posada and Barriales). 1999;138:137-43
Bart BA, Goldsmith SR. Aggravated renal dysfunction and the acute management of advanced chronic heart failure. 1999; 138:200-2
Bart BA. Concern for azotemia with angiotensin-converting enzyme inhibitors: public health implications and clinical relevance. 1999; 138:801-3 (Editorial)
Barth H (*see* Spiecker et al). 1999;138:518-24
Bashore TM (*see* Hochrein et al). 1999;138:791-7
Bashore TM (*see* Wang et al). 1999;138:777-84
Bassett JS (*see* Redle et al). 1999;138:144-50
Basu A (*see* Cooper et al). 1999;38:430-6
Batchelor WB, Zidar JP. Favorable vascular remodeling from self-expanding stents: magic or myth? 1999;138:203-5
Baumbach A (*see* Schroeder et al). 1999;138:731-9
Bazzino O. Defining risk in unstable angina. 1999;138:1198 (Letter reply)
Beachler L (*see* Pasquet et al). 1999;138:753-8

Beck JD, Pankow J, Tyroler HA, Offenbacher S. Dental infections and atherosclerosis. 1999;138:S529-S533
Beller GA (*see* Sias et al). 1999;138:206-9 (Editorial)
Bello D, Shah NB, Edep ME, Tateo IM, Massie BM. Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure. 1999;138:100-7
Berenson GS (*see* Urbina et al). 1999;138:122-7
Berg A (*see* Halle et al). 1999;138:309-12
Berg G (*see* Glunz et al). 1999;138:1111-7
Berg G (*see* Tebbe et al). 1999;138:S39-S44
Berkowitz SD (*see* Madan and Berkowitz). 1999;138:S317-S326
Berliner S (*see* Kassirer et al). 1999;138:555-9
Berman (*see* Kang et al). 1999;138:1025-32
Bernstein L (*see* Qamar et al). 1999;138:705-9
Bethout F (*see* Jarrar et al). 1999;138:950-4
Bethel MA (*see* Feinglos et al). 1999;138:S346-S352
Bethel MA (*see* Rao et al). 1999;138:S334-S338
Betsuyaku T (*see* Sato et al). 1999;138:560-6
Beyar R (*see* Roguin et al). 1999;138:326-33
Bhargava V (*see* Arbab-Zadeh et al). 1999;138:865-72
Bhatt DL, Ellis SG, Ivanc TB, Crowe T, Balazs E, Debowey D, Pangerl A, Chew PH. Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction. 1999;138:785-90
Birkelund S (*see* Christiansen et al). 1999;138:S491-S495
Bittner V. Determining prognosis in congestive heart failure: role of the 6-minute walk test. 1999;138:593-6 (Editorial)
Blaesing L (*see* Cooper et al). 1999;38:430-6
Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. 1999;138:S287-S296
Blazing MA (*see* Orloff et al). 1999;138:S406-S412
Blessing E, Hausmann D, Sturm M, Wolpers H-G, Amende I, Mügge A. Observerrelated variability in IVUS measurements after stenting. 1999;138:1199 (Letter reply)
Blue L (*see* Murdoch et al). 1999;138:1126-32
Boehm M (*see* Suedkamp et al). 1999;138:269-72
Boesen T (*see* Christiansen et al). 1999;138:S491-S495
Boigtländer T (*see* Glunz et al). 1999;138:1111-7
Boler S. (*see* Twidale et al). 1999;138:1166-75
Bolognese L (*see* Antoniucci et al). 1999;138:670-4
Bolognese L, Cerisano G. Early predictors of left ventricular remodeling after acute myocardial infarction. 1999;138:S79-S83
Bonaduce D, Petretta M, Marciano F, Vicario MLE, Apicella C, Rao MAE, Nicolai E, Volpe M. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. 1999;138:273-84
Booth JE (*see* Scirica et al). 1999;138:1065-72
Boothroyd DB (*see* Hlatky et al). 1999;138:376-83
Bors V (*see* Leprince et al). 1999;138:586-92
Borzak S. No time to wait. 1999;138:1003-4
Boudifa A (*see* Leprince et al). 1999;138:586-92
Bozovich G (*see* Gurfinkel and Bozovich). 1999;138:S537-S538
Braden GA (*see* Tcheng et al). 1999;138:S33-S38
Brawner CA (*see* Keteyian et al). 1999;138:233-40
Brewer TJ (*see* Khaw et al). 1999;138:934-40
Briguori C (*see* Colombo and Briguori). 1999;138:S153-S157
Briguori C, Di Mario C, De Gregorio J, Sheiban I, Vaghetti M, Colombo A. Administration of protamine after coronary stent deployment. 1999;138:64-8
Brooks DP, Ohlstein EH, Ruffolo Jr RR. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. 1999;138:S246-S251
Brooks MM (*see* Hlatky et al). 1999;138:376-83
Brown MW (*see* Nakamura et al). 1999;138:500-6
Brown MW (*see* Nakamura et al). 1999;138:577-85
Bruggeman C. Cytomegalovirus is involved in vascular pathology. 1999;138:S473-S475
Brunham RC, Zhang D. Transgene as vaccine for *chlamydia*. 1999;138:S519-S522
Brunner H (*see* Julus and Brunner). 1999;138:S203-S204
Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Candinas R, Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohomone levels in patients with chronic heart failure. 1999;138:654-62
Buchholz-Varley C (*see* Kukin et al). 1999;138:261-8
Büchler JR (*see* Pessotto et al). 1999;138:1184-95
Buonamici P (*see* Santoro and Buonamici). 1999;138:S126-S131
Burgos J (*see* Morales et al). 1999;138:291-8
Burket MW (*see* Cooper et al). 1999;38:430-6
Burnette JC (*see* Burnett et al). 1999;138:1140-8
Butt RW (*see* Parker et al). 1999;138:843-8
Byrne GI, Kalayoglu MV. Chlamydia pneumoniae and atherosclerosis: links to the disease process. 1999;138:S488-S490
Byrne J (*see* Murdoch et al). 1999;138:1126-32

C

Calabró R, Pisacane C, Pacileo G, Giovanna Russo M. Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. 1999;138:955-61
Califf RM. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. 1999;138:S12-S15
Califf RM (*see* Mahaffey et al). 1999;138:493-9
Califf RM (*see* Gilchrist et al). 1999;138:976-82
Califf RM (*see* Hasdai et al). 1999;138:21-31
Califf RM (*see* O'Connor et al). 1999;138:78-86
Califf RM (*see* McGuire and Califf). 1999;138:S327-S329
Califf RM, Holmes Jr DR. Should the emergency of new agents change the management of patients with acute coronary syndromes without ST-segment elevation? 1999;138:S586-S594
Caligiuri G (*see* Nicoletti et al). 1999;138:S438-S443
Cambier PA (*see* Fung et al). 1999;138:696-704
Campbell LA, Kuo C. Mouse models of Chlamydia pneumoniae infection and atherosclerosis. 1999;138:S517-S518
Campbell LA. How to design studies to confirm a link between bacterial infection and atherosclerosis. 1999;138:S552-S553
Canale MP (*see* Klein et al). 1999;138:880-9
Candinas R (*see* Brunner-La Rocca et al). 1999;138:654-62
Cannon CP (*see* Scirica et al). 1999;138:1065-72
Cantor W (*see* Alexander et al). 1999;138:175-90
Capron L. How to design vaccination trials to prevent atherosclerosis. 1999;138:S558-S559
Cardoso LF (*see* Tarasoutchi et al). 1999;138:477-85
Carinci F (*see* Fresco et al). 1999;138:1058-64
Carlson MD (*see* Geller et al). 1999;138:987-93
Carrier S (*see* Twidale et al). 1999;138:1166-75
Carruthers SG. Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas? 1999;138:S256-S260
Carter AJ (*see* Sangiorgi et al). 1999;138:681-7
Cascio WE (*see* Jollis et al). 1999;138:S376-S380
Catellier DJ (See Teo et al). 1999;138:400-2 (Editorial)
Ceconi C (*see* Ferrari et al). 1999;138:S61-S68
Cenarrao A (*see* Civeira et al). 1999;138:156-62
Cerisano G (*see* Bolognese and Cerisano). 1999;138:S79-S83
Chae JK (*see* Lee et al). 1999;138:S60-S63
Chambless LE (*see* White et al). 1999;138:540-8
Chapko MK (*see* Ritchie et al). 1999;138:437-40
Chavez E (*see* Corbalán et al). 1999;138:533-9
Chen SC (*see* Franzini et al). 1999;138:414-21
Chen YT (*see* Vaccarino et al). 1999;138:835-42
Cheng TO. Confusion in geography. 1999;138:1196 (Letter)
Cheng TO. The People's Republic of China. 1999;138:1196-7 (Letter)
Chern MS (*see* Hung et al). 1999;138:114-21
Chertow GM (*see* Weinfeld et al). 1999;138:285-90
Cheung L (*see* McAlister et al). 1999;138:87-94

Chew PH (*see* Bhatt et al). 1999;138:785-90
Chisin R (*see* Rozenman et al). 1999;138:441-5
Chiu B. Multiple infections in carotid atherosclerotic plaques. 1999;138:S534-S536
Chou TM (*see* Stahl et al). 1999;138:1200 (Letter)
Chowdhury MK (*see* Jollis et al). 1999;138:S376-S380
Christiansen G, Boesen T, Hjernø K, Daugaard L, Mygind P, Madsen AS, Knudsen K, Falk E, Birkelund S. Molecular biology of *Chlamydia pneumoniae* surface proteins and their role in immunopathogenicity. 1999;138:S491-S495
Chronakis EV (*see* Makris et al). 1999;138:922-5
Ciampi A (*see* Fresco et al). 1999;138:1058-64
Cintron G (*see* Vesely et al). 1999;138:625-32
Civeira F, Cenarro A, Ferrando J, Puzo J, Garcia-Otín AL, Mozas P, Pocoví M. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. 1999;138:156-62
Clark Jr CM, Perry RC. Type 2 diabetes and macrovascular disease: epidemiology and etiology. 1999;138:S330-S333
Cody RJ (*see* Burnett et al). 1999;138:1140-8
Cohen DJ (*see* Cooper et al). 1999;38:430-6
Cohen I (*see* Kang et al). 1999;138:1025-32
Cohen M (*see* Antman and Cohen). 1999;138:S563-S569
Cohen MC, Stafford RS, Misra B. Stress testing: national patterns and predictors of test ordering. 1999;138:1019-24
Cokkinos P (*see* Tousoulis et al). 1999;138:873-9
Coller BS. Potential non-glycoprotein IIb/IIIa effects of abciximab. 1999;138:S1-S5
Collins TJ (*see* Silva et al). 1999;138:446-55
Colombo A, Briguori C. Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction. 1999;138:S153-S157
Colombo A (*see* Briguori et al). 1999;138:64-8
Colombo A (*see* Dangas and Colombo). 1999;138:S16-S23
Comeglio M (*see* Gensini et al). 1999;138:S171-S176
Conti AA (*see* Michelucci et al). 1999;138:128-32
Conwill D (*see* White et al). 1999;138:540-8
Cooklin M, Tummala RV, Peters RW, Shorofsky SR, Gold MR. Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. 1999;138:133-6
Cooper CJ, El-Shiekh A, Cohen DJ, Blaesing L, Burket MW, Basu A, Moore JA. Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison. 1999; 38:430-6
Cooper LS (*see* Goff et al). 1999;138:1046-57
Cooper LS (*see* White et al). 1999;138:540-8
Corbalán R, Prieto JC, Chavez E, Nazzal C, Cumsille F, Krucoff M. Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis. 1999;138:533-9
Cornell CE (*see* Goff et al). 1999;138:1046-57
Cortes J (*see* Escaned et al). 1999;138:675-80
Craig CA (*see* Baker et al). 1999;138:826-34
Crain J (*see* Twidale et al). 1999;138:1166-75
Crouse III JR (*see* Jollis et al). 1999;138:S376-S380
Crouse LJ, Kramer PH. Second harmonic imaging: good reverberations. 1999;138:19-20 (Editorial)
Crowe T (*see* Bhatt et al). 1999;138:785-90
Cuffe MS. Lyme disease: an active agent in dilated cardiomyopathy? 1999;138:198-9 (Editorial)
Culler S (*see* Weintraub et al). 1999;138:S394-S399
Cumsille F (*see* Corbalán et al). 1999;138:533-9
Curello S (*see* Ferrari et al). 1999;138:S61-S68
Curtis LH (*see* Nash et al). 1999;138:422-9

D

D'Agostino RB (*see* Sherman et al). 1999;138:900-7
da luz PL (*see* Tarasoutchi et al). 1999;138:477-85
Dal Bello B (*see* Arbustini et al). 1999;138:S55-S60
Dalianis N (*see* Hatzizacharias et al). 1999;138:241-6
Danesh J. Coronary heart disease, helicobacter pylori, dental disease, *Chlamydia pneumoniae*, and cytomegalovirus: meta-analyses of prospective studies. 1999;138:S434-S437
Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA. Effects of platelet gylcoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. 1999;138:49-54
Dangas G, Colombo A. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. 1999;138:S16-S23
Danias PG (*see* Pescatello et al). 1999;138:916-21
Dargie HJ (*see* Murdoch et al). 1999;138:1126-32
Dargie HJ (*see* Northridge et al). 1999;138:1149-57
Daugaard L (*see* Christiansen et al). 1999;138:S491-S495
Davidoff R (*see* Mendes et al). 1999;138:303-8
Davies G (*see* Tousoulis et al). 1999;138:873-9
De Leon J (*see* Dangas et al). 1999;138:49-54
De Souza MJ (*see* Pescatello et al). 1999;138:916-21
De Gregorio J (*see* Briguori et al). 1999;138:64-8
De La Fuente B (*see* Hochman et al). 1999;138:313-8
Debowey D (*see* Bhatt et al). 1999;138:785-90
Dec GW (*see* Mendes et al). 1999;138:303-8
Degawa T (*see* Sakatani et al). 1999;138:962-7
Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. 1999;138:646-53
DeMaria AN (*see* Arbab-Zadeh et al). 1999;138:865-72
DeNofrio D. Natriuretic peptides for treatment of congestive heart failure. 1999;138:597-8 (Editorial)
Derchi G, Fonti A. Pulmonary hypertension in patients with thalassemia major. 1999;138:384 (Letter)
DeRobertis M (*see* Khan et al). 1999;138:108-13
Deutsch E The emerging role of low-molecular-weight heparin in the cardiac catheterization lab. 1999;138:S577-S585
Deutsch HJ (*see* Hoepp et al). 1999;138:941-9
Dhall A (*see* Kalra et al). 1999;138:339-44
Di Mario C (*see* Briguori et al). 1999;138:64-8
Dietz JR (*see* Vesely et al). 1999;138:625-32
Dockery DW (*see* Pope et al). 1999;138:890-9
Dodet B, Plotkin S. Infection and atherosclerosis. 1999;138:S417-S418
Domitrovich PP (*see* Stein et al). 1999;138:567-76
Dorent R (*see* Leprince et al). 1999;138:586-92
Drennan S (*see* Pracyk et al). 1999;138:1014-5
Dronmal RA (*see* Grayston et al). 1999;138:S545-S549
Du Z-D (*see* Derchi and Fonti). 1999;138:384 (Letter reply)
Dunne M. WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics. 1999;138:S542-S544
Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective. 1999;138:S307-S316

E

Eagen-Bengsten E (*see* Lucas et al). 1999;138:618-24
Eagle KA (*see* Mehta et al). 1999;138:688-95
Edep ME (*see* Bello et al). 1999;138:100-7
Edwards WD (*see* Sangiorgi et al). 1999;138:681-7
Effron MB (*see* Tcheng et al). 1999;138:S33-S38
Egstrup K (*see* Poulsen et al). 1999;138:710-20
Ehsani AA (*see* Rinder et al). 1999;138:169-74
Ehsani AA (*see* Stein et al). 1999;138:567-76
Eichhorn RJ. β-Blocker withdrawal: the song of Orpheus. 1999;138: 387-9 (Editorial)
Eiffert H (*see* Suedkamp et al). 1999;138:269-72
Einfalt JM (*see* Kaufmann et al). 1999;138:549-54
El-Shiekh A (*see* Cooper et al). 1999;38:430-6
Eldor A (*see* Kassirer et al). 1999;138:555-9
Elkasabany A (*see* Urbina et al). 1999;138:122-7

Elkayam U (*see* Burnett et al). 1999;138:1140-8
Ellenbogen KA (*see* Melton et al). 1999;138:1016-8
Ellis SG (*see* Bhatt et al). 1999;138:785-90
Enderle MD (*see* Schroeder et al). 1999;138:731-9
Epstein SE, Zhou YF, Zhu J. Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis. 1999;138: S476-S478
Escaned J, Cortes J, Alcocer MA, Goicolea J, Alfonso F, Fernandez-Ortiz A, Hernandez R, Bañuelos C, Macaya C. Long-term angiographic results of stenting in chronic total occlusions: influence of stent design and vessel size. 1999;138:675-80
Evangelista A (*see* Mercé et al). 1999;138:759-64
Every NR (*see* Ritchie et al). 1999;138:437-40
Every NR (*see* Fung et al). 1999;138:696-704
Every NR (*see* Scirica et al). 1999;138:1065-72
Ezekowitz MD (*see* Howes and Ezekowitz). 1999;138:13 (Editorial)

F

Fabricant CG, Fabricant J. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. 1999;138:S465-S468
Fabricant J (*see* Fabricant and Fabricant). 1999;138:S465-S468
Falai M (*see* Gensini et al). 1999;138:S171-S176
Falk E. Stable versus unstable atherosclerosis: clinical aspects. 1999;138:S421-S425
Falk E (*see* Christiansen et al). 1999;138:S491-S495
Farb A (*see* Sangiorgi et al). 1999;138:681-7
Farhat MB (*see* Jarrar et al). 1999;138:950-4
Farmer R (*see* Murdoch et al). 1999;138:1126-32
Fazzini PF (*see* Antoniucci et al). 1999;138:670-4
Fedi S (*see* Michelucci et al). 1999;138:128-32
Feinglos MN (*see* Rao et al). 1999;138:S334-S338
Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. 1999;138:S346-S352
Feldman D (*see* Dangas et al). 1999;138:49-54
Feldman HA (*see* Goff et al). 1999;138:1046-57
Ferguson JJ, Taqi K. IIb/IIIa Receptor blockade in acute myocardial infarction. 1999;138:S164-S170
Ferguson JJ (*see* Scirica et al). 1999;138:1065-72
Fernández-Guerra J (*see* Morales et al). 1999;138:291-8
Fernandez-Ortiz A (*see* Escaned et al). 1999;138:675-80
Ferrando J (*see* Civeira et al). 1999;138:156-62
Ferrari R, Ceconi C, Curello S, Percoco G, Toselli T, Antonioli G. Ischemic preconditioning, myocardial stunning, and hibernation: basic aspects. 1999;138:S61-S68
Ferrario M, Repetto A, Lucreziotti S, Ardissino D. Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction. 1999;138:S121-S125
Ferris ST (*see* Lehmann et al). 1999;138:1118-25
Filho JP (*see* Tarasoutchi et al). 1999;138:477-85
Filmont JE (*see* Hamon et al). 1999;138:55-9
Fineberg N (*see* Wilensky et al). 1999;138:319-25
Fink G (*see* Zafrir et al). 1999;138:1088-92
Fitzgibbons JP (*see* Kaufmann et al). 1999;138:549-54
Flack JM, Gardin JM, Yunis C, Liu K. Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study. 1999;138:856-64
Flack JM, Kvasnicka JH, Gardin JM, Gidding SS, Manolio TA, Jacobs Jr DR. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. 1999;138:486-92
Flemin A. FDA approach to the regulation of drugs for diabetes. 1999;138:S339-S345
Flesch M (*see* Suedkamp et al). 1999;138:269-72
Follath F (*see* Brunner-La Rocca et al). 1999;138:654-62
Folsom AR (*see* White et al). 1999;138:540-8
Fong IW. Value of animal models for *Chlamydia pneumoniae*-related atherosclerosis. 1999;138:S512-S513
Fonti A (*see* Derchi and Fonti). 1999;138:384 (Letter)
Foroushani F (*see* Ardehali et al). 1999;138:983-6
Foryski F (*see* Tebbe et al). 1999;138:S39-S44
Francis GS. Is there still a future for neutral endopeptidase inhibitors? 1999;138:1007-8
Frane AM (*see* Murdock et al). 1999;138:151-5
Franzini L, Chen SC, McGhie AI, Low MD. Assessing the cost of a cardiology residency program with a cost construction model. 1999;138:414-21
Fresco C, Carinci F, Maggioni AP, Ciampi A, Nicolucci A, Santoro E, Tavazzi L, Tognonia G. Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction. 1999;138:1058-64
Fretz C (*see* Leprince et al). 1999;138:586-92
Freudenberger RS (*see* Kukin et al). 1999;138:261-8
Fricchione GL (*see* Kaufmann et al). 1999;138:549-54
Friday G (*see* Goldstein et al). 1999;138:1158-65
Friedman EH. Defining risk in unstable angina. 1999;138:1197-8 (Letter)
Friedman JD (*see* Kang et al). 1999;138:1025-32
Frimerman A (*see* Kassirer et al). 1999;138:555-9
Frumin HI (*see* Redle et al). 1999;138:144-50
Fujii K (*see* Tamai et al). 1999;138:968-75
Fung AY, Lorch G, Cambier PA, Hansen D, Titus BG, Martin JS, Lee JJ, Every NR, Hallstrom AP, Stock-Novack D, Scherer J, Weaver WD. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. 1999;138:696-704
Furberg CD. Hypertensions and diabetes: current issues. 1999; 138:S400-S405

G

Gamra H (*see* Jarrar et al). 1999;138:950-4
Gandjbakhch I (*see* Leprince et al). 1999;138:586-92
Gantner SE (*see* Murdock et al). 1999;138:151-5
Garcia-Otín AL (*see* Civeira et al). 1999;138:156-62
Gardin JM (*see* Flack et al). 1999;138:486-92
Gardin JM (*see* Flack et al). 1999;138:856-64
Gardner LH (*see* Gilchrist et al). 1999;138:976-82
Garg R, Malinow R, Pettinger M, Upson B, Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. 1999;138:1082-7
Garratt KN (*see* Mathew et al). 1999;138:1105-10
Gates KB (*see* Pettis et al). 1999;138:765-70
Gattis WA (*see* O'Connor et al). 1999;138:78-86
Gattis WA (*see* Burnett et al). 1999;138:1140-8
Gavrila D (*see* Hochman et al). 1999;138:313-8
Gaydos CA (*see* Quinn and Gaydos). 1999;138:S507-S511
Geller JC, Carlson MD, Goette A, Reek S, Hartung WM, Klein HU. Persistent T-wave changes after radiofrequency catheter ablation of an accessory connection (Wolff-Parkinson-White syndrome) are caused by "cardiac memory." 1999;138:987-93
Gensini GF, Comeglio M, Falai M. Advances in antithrombotic therapy of acute myocardial infarction. 1999;138:S171-S176
Gensini GF (*see* Michelucci et al). 1999;138:128-32
German G (*see* Kang et al). 1999;138:1025-32
Germing A (*see* Machraoui et al). 1999;138:663-9
Gersh BJ. Optimal management of acute myocardial infarction at the dawn of the next millennium. 1999;138:S188-S202
Ghali JK. Contemporary issues in heart failure. 1999;138:5-8 (Editorial)
Gheorghiade M (*see* Goldstein et al). 1999;138:1158-65
Gheorghiade M (*see* Burnett et al). 1999;138:1140-8
Gheorghiade M (*see* O'Connor et al). 1999;138:78-86
Gibson CM. The sundial and the stopwatch. 1999;138:614-17 (Editorial)
Gidding SS (*see* Flack et al). 1999;138:486-92

Gidding SS (*see* Urbina et al). 1999;138:122-7
Gilbert J (*see* Burnett et al). 1999;138:1140-8
Gilchrist IC, Gardner LH, Muhlestein JB, Arnold AM, Lincoff AM, Califf RM, Tcheng JE, Topol EJ. Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. 1999;138:976-82
Ginzton LE (*see* Oudiz et al). 1999;138:369-75
Giovanna Russo M (*see* Calabró et al). 1999;138:955-61
Glower DD (*see* Hochrein et al). 1999;138:791-7
Glunz HG (*see* Glunz et al). 1999;138:1111-7
Glynn RJ (*see* Knight et al). 1999;138:849-55
Godleski JJ (*see* Stone and Godleski). 1999;138:804-7 (Editorial)
Goette A (*see* Geller et al). 1999;138:987-93
Goff JR DC, Feldman HA, McGovern PG, Goldberg RJ, Simons-Morton DG, Cornell CE, Osganian SK, Cooper LS, Hedges JR. Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. 1999;138:1046-57
Goh T (*see* Janorkar et al). 1999;138:1176-83
Goicolea J (*see* Escaned et al). 1999;138:675-80
Gold DR (*see* Pope et al). 1999;138:890-9
Gold MR (*see* Cooklin et al). 1999;138:133-6
Goldberg RJ (*see* Goff et al). 1999;138:1046-57
Goldhaber SZ. Pulmonary embolism thrombolysis: do we need another agent? 1999;138:1-2 (Editorial)
Goldmann B (*see* Schuchert et al). 1999;138:45-8
Goldsmith SR (*see* Bart and Goldsmith). 1999;138:200-2 (Editorial)
Goldstein S (*see* Keteyian et al). 1999;138:233-40
Goldstein S (*see* Ali et al). 1999;138:1133-9
Goldstein S (*see* Burnett et al). 1999;138:1140-8
Goldstein S, Kennedy HL, Hall C, Anderson JL, Gheorghiade M, Gottlieb S, Jessup M, Karlsberg RP, Friday G, Haskell L. Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety and effect on left ventricular ejection fraction. 1999;138:1158-65
Gore JM (*see* Mahaffey et al). 1999;138:493-9
Gorscan III J (*see* Mankad et al). 1999;138:721-30
Gotsman MS (*see* Rozenman et al). 1999;138:441-5
Götte MJ, van Rossum AC, Marcus JT, Kuijer JPA, Axel L, Visser CA. Recognition of infarct localization by specific changes in intramural myocardial mechanics. 1999;138:1038-45
Gottlieb S (*see* Goldstein et al). 1999;138:1158-65
Gottwik M (*see* Glunz et al). 1999;138:1111-7
Graf A (*see* Tebbe et al). 1999;138S39-S44
Granger CB (*see* Scirica et al). 1999;138:1065-72
Granger CB (*see* Mahaffey et al). 1999;138:493-9
Granger CB (*see* McGuire and Granger). 1999;138:S366-S375
Granger CB (*see* Burnett et al). 1999;138:1140-8
Grayston JT. Design of future intervention studies for *Chlamydia pneumoniae* in atherosclerosis. 1999;138:S556-S557
Grayston JT, Jackson LA, Kennedy WJ, Kronmal RA. Secondary prevention trials for coronary artery disease with antibiotic treatment for *Chlamydia pneumoniae*: design issues. 1999; 138:S545-S549
Green CL (*see* Mahaffey et al). 1999;138:493-9
Greenbaum AB (*see* Alexander et al). 1999;138:175-90
Gregory PM, Rhoads GG, Wilson AC, O'Dowd KJ, Kostis JB. Impact of availability of hospital-based invasive cardiac services on racial differences in the use of these services. 1999; 138:507-17
Grenadier E (*see* Roguin et al). 1999;138:326-33
Grinberg M (*see* Tarasoutchi et al). 1999;138:477-85
Grobbee DE (*see* Moons et al). 1999;138:525-32
Grollier G (*see* Hamon et al). 1999;138:55-9
Grossman SH (*see* O'Connor et al). 1999;138:78-86
Guazzi M, Agostoni P, Matturri M, Pontone G, Guazzi MD. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. 1999;138:460-7
Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. 1999;138:254-60
Guazzi MD (*see* Guazzi et al). 1999;138:460-7
Guerin AP (*see* London and Guerin). 1999;138:S220-S224
Gupta S. *Chlamydia pneumoniae*, monocyte activation, and azithromycin in coronary heart disease. 1999;138:S539-S541
Gurfinkel EP, Bozovich G. Emerging role of antibiotics in atherosclerosis. 1999;138:S537-S538
Guyton JR. Treatment of type III hyperlipoproteinemia. 1999;138: 17-18 (Editorial)

H

Habbema DF (*see* Moons et al). 1999;138:525-32
Hachamovitch R (*see* Kang et al). 1999;138:1025-32
Haering HU (*see* Schroeder et al). 1999;138:731-9
Hajjar DP (*See* Nicholson and Hajjar). 1999;138:S461-S464
Hall WD. Risk reduction associated with lowering systolic blood pressure: review of clinical trial data. 1999;138:S225-S230
Hall C (*see* Goldstein et al). 1999;138:1158-65
Halle M, Huonker M, Hohnloser SH, Alivertis M, Berg A, Keul J. QT dispersion in exercise-induced myocardial hypertrophy. 1999;138:309-12
Hallstrom AP (*see* Fung et al). 1999;138:696-704
Hamda KB (*see* Jarrar et al). 1999;138:950-4
Hamilton MA (*see* Lucas et al). 1999;138:618-24
Hamm C (*see* Schuchert et al). 1999;138:45-8
Hamm CW. Risk stratifying acute coronary syndromes: gradient of risk and benefit. 1999;38:S6-S11
Hammami S (*see* Jarrar et al). 1999;138:950-4
Hamon M, Richardeau Y, Lécluse E, Saloux E, Sabatier R, Agostini D, Filmont JE, Grollier G, Potier JC. Direct coronary stenting without balloon predilation in acute coronary syndromes. 1999;138:55-9
Hansen D (*see* Fung et al). 1999;138:696-704
Hansson GK (*see* Nicoletti et al). 1999;138:S438-S433
Harrington RA. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. 1999;138:S276-S286
Harrison JK (*see* Wang et al). 1999;138:777-84
Harrison JK (*see* Hochrein et al). 1999;138:791-7
Harrison JK (*see* O'Laughlin and Harrison). 1999;138:808-9 (Editorial)
Hartley H (*see* Lucas et al). 1999;138:618-24
Hartung WM (*see* Geller et al). 1999;138:987-93
Hartz VL (*see* Mendes et al). 1999;138:303-8
Hasdai D, Holmes Jr DR, Califf RM, Thompson TD, Hochman JS, Pfisterer M, Topol EJ. Cardiogenic shock complicating acute myocardial infarction: predictors of death. 1999;138:21-31
Hasin Y (*see* Rozenman et al). 1999;138:441-5
Haskell L (*see* Goldstein et al). 1999;138:1158-65
Hatzizacharias A, Makris T, Krespi P, Triposkiadis F, Voyatzi P, Dalianis N, Kyriakidis M. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. 1999;138:241-6
Hatzizacharias AN (*see* Makris et al). 1999;138:922-5
Hauptmann KE (*see* Glunz et al). 1999;138:1111-7
Hausmann D (*see* Blessing et al). 1999;138:1199 (Letter)
Hayes RP (*see* Baker et al). 1999;138:826-34
He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. 1999;138:S211-S219
Heath-Lange SJ (*see* Lehmann et al). 1999;138:1118-25
Hedges JR (*see* Goff et al). 1999;138:1046-57
Heidenreich PA, Ruggerio CM, Massie BM. Effect of a home monitoring system on hospitalization and resource use for patients with heart failure. 1999;138:633-40
Herdeg C (*see* Schroeder et al). 1999;138:731-9
Hernandez R (*see* Escaned et al). 1999;138:675-80

Hess M (*see* Pescatello et al). 1999;138:916-21
Hikita H (*see* Koyama et al). 1999;138:468-76
Hilders K (*see* Schlaich et al). 1999;138:810-17
Hillegass WB, Newman AR, Raco DL. Economic issues in glycoprotein IIb/IIIa receptor therapy. 1999;138:S24-S32
Hiramitsu S (*see* Uemura et al). 1999;138:299-302
Hiramitzu S (*see* Morimoto et al). 1999;138:456-9
Hishida H (*see* Uemura et al). 1999;138:299-302
Hishida J (*see* Morimoto et al). 1999;138:456-9
Hjernø K (*see* Christiansen et al) 1999;138:S491-S495
Hlatky MA, Boothroyd DB, Brooks MM, Winston C, Rosen A, Rogers WJ, Reeder GS, Smith HC, Ryan TJ, Pitt B, Whitlow PL, Wiens RD, Mark DB. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. 1999;138:376-83
Hochman JS, Wali AU, Gavrila D, Sim MJ, Malhotra S, Palazzo AM, De La Fuente B. A new regimen for heparin use in acute coronary syndromes. 1999;138:313-8
Hochman JS (*see* Hasdai et al). 1999;138:21-31
Hochrein J, Lucke JC, Harrison JK, Bashore TM, Wolfe WG, Jones RH, Lowe JE, White WD, Glower DD. Mortality and need for reoperation in patients with mild-to-moderate asymptomatic aortic valve disease undergoing coronary artery bypass graft alone. 1999;138:791-7
Hodinka RL. Designing studies to confirm a link between viral infection and atherosclerosis. 1999;138:S554-S555
Hoepp HW, Deutsch HJ, La Rosée K, Schnabel P, Terheggen G, Schneider CA, Korsten J, Babic UU. Transcatheter closure of atrial-septal defects and patent foramen ovale in adults: optimal anatomic adaptation of occlusion device. 1999;138:941-9
Hohnloser SH (*see* Halle et al). 1999;138:309-12
Hojo Y (*see* Ikeda et al). 1999;138:1199 (Letter)
Holliday R (*see* Twidale et al). 1999;138:1166-75
Holman RR (*see* Adler et al). 1999;138:S353-S359
Holmes DR (*see* Sangiorgi et al). 1999;138:681-7
Holmes Jr DR (*see* Hasdai et al). 1999;138:21-31
Holmes Jr DR (*see* Mathew et al). 1999;138:1105-10
Holmes Jr DR (*see* Califf et al). 1999;138:S586-S594
Holmes Jr DR (*see* Rihal and Holmes). 1999;138:392-3 (Editorial)
Hong MK (*see* Lee et al). 1999;138:S60-S63
Hongo Y, Tada H, Ito K, Yasumura Y, Miyatake K, Yamagishi M. Augmentation of vessel squeezing at coronary-myocardial bridge by nitroglycerin: study by quantitative coronary angiography and intravascular ultrasound. 1999;138:345-50
Hopkins GR (*see* Spiecker et al). 1999;138:518-24
Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. 1999;138:S469-S472
Hosler MN (*see* Khaw et al). 1999;138:934-40
Howes CJ, Ezekowitz MD. Alternate-day dosing of aspirin in atrial fibrillation: a critical evaluation. 1999;138:13 (Editorial)
Hu W (*see* Zeng et al). 1999;138:1197 (Letter reply)
Hudson MP (*see* Alexander et al). 1999;138:175-90
Humen D (*see* McAlister et al). 1999;138:87-94
Humen DP (*see* Parker et al). 1999;138:843-8
Hung JS, Lau KW, Lo PH, Chern MS, Wu JJ. Complications of Inoue balloon mitral commissurotomy: impact of operator experience and evolving technique. 1999;138:114-21
Hunninghake D (*see* Garg et al). 1999;138:1082-7
Huonker M (*see* Halle et al). 1999;138:309-12

I

Ikeda S (*see* Koyama et al). 1999;138:468-76
Ikeda U. Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. 1999;138:1199 (Letter)
Ikonomidis I (*see* Rallidis et al). 1999;138:351-7
Isner JM (*see* Losordo et al). 1999;138:S132-S141
Ito K (*see* Hongo et al). 1999;138:345-50
Ito T (*see* Uemura et al). 1999;138:299-302
Ito T (*see* Sato et al). 1999;138:560-6
Ivanc TB (*see* Bhatt et al). 1999;138:785-90
Izaki M (*see* Tarasoutchi et al). 1999;138:477-85

J

Jackson LA (*see* Grayston et al). 1999;138:S545-S549
Jacobs AK (*see* Ryan et al). 1999;138:S96-S104
Jacobs Jr DR (*see* Flack et al). 1999;138:486-92
Jaffe AS. Pandora's box is torn asunder. 1999;138:9-12 (Editorial)
Jäger D (*see* Machraoui et al). 1999;138:663-9
Jain SP (*see* Silva et al). 1999;138:446-55
Janorkar S, Goh T, Wilkinson J. Transcatheter closure of patent ductus arteriosus with the use of Rashkind occluders and/or Giantruco coils: long-term follow-up in 123 patients with special reference to comparison, residual shunts, complications, and technique. 1999;138:1176-83
Jarrar M, Betbout F, Farhat MB, Maatouk F, Gamra H, Addad F, Hammami S, Hamda KB. Long-term invasive and noninvasive results of percutaneous balloon pulmonary valvuloplasty in children, adolescents, and adults. 1999;138:950-4
Jenkins JS (*see* Silva et al). 1999;138:446-55
Jensen SE (*see* Poulsen et al). 1999;138:710-20
Jessup M (*see* Goldstein et al). 1999;138:1158-65
Johnson JA (*see* Son et al). 1999;138:358-63
Johnson W (*see* Lucas et al). 1999;138:618-24
Jollis JG, Simpson Jr RJ, Cascio WE, Chowdhury MK, Crouse III JR, Smith Jr SC. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. 1999;138:S376-S380
Jollis JG. Practice still makes perfect. 1999;138:394-5 (Editorial)
Jollis JG (*see* Anstrom et al). 1999;138:1001-2
Jones RH (*see* Hochrein et al). 1999;138:791-7
Jordan RE (*see* Tcheng et al). 1999;138:S33-S38
Jourdan J (*see* Leprince et al). 1999;138:586-92
Joyce DM (*see* Murdock et al). 1999;138:151-5
Julius S, Brunner H. Introduction. 1999;138:S203-S204
Juran NB. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy. 1999;138:S297-S306

K

Kadoba K (*see* Pessotto et al). 1999;138:1184-95
Kalayoglu MV (*see* Byrne and Kalayoglu). 1999;138:S488-S490
Kalman J (*see* Kukin et al). 1999;138:261-8
Kalra GS, Verma PK, Dhall A, Singh S, Arora R. Transcatheter device closure of ventricular septal defects: immediate results and intermediate-term follow-up. 1999;138:339-44
Kamke W (*see* Tebbe et al). 1999;138:S39-S44
Kang X, Berman DS, Lewin HC, Cohen I, Friedman JD, Germano G, Hachamovitch R, Shaw LJ. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. 1999;138:1025-32
Kannel WB (*see* Sherman et al). 1999;138:900-7
Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. 1999;138:S205-S210
Kanner RE (*see* Pope et al). 1999;138:890-9
Karlsberg RP (*see* Goldstein et al). 1999;138:1158-65
Karsch KR (*see* Schroeder et al). 1999;138:731-9
Kasper EK (*see* Burnett et al). 1999;138:1140-8
Kass R (*see* Khan et al). 1999;138:108-13
Kassirer M, Zeltser D, Prochorov V, Schoenman G, Frimerman A,

Keren G, Shapira I, Miller H, Roth A, Arber N, Eldor A, Berliner S. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. 1999;138:555-9
Kato Y (*see* Uemura et al). 1999;138:299-302
Katoh O (*see* Tamai et al). 1999;138:968-75
Katsuki T (*see* Ikeda et al). 1999;138:1199 (Letter)
Katz A, Liberty IF, Porath A, Ovsysheher I, Prystowsky EN. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. 1999;138:32-8
Katz SD (*see* Burnett et al). 1999;138:1140-8
Kaufmann MW, Fitzgibbons JP, Sussman EJ, Reed III JF, Einfalt JM, Rodgers JK, Fricchione GL. Relation between myocardial infarction, depression, hostility, and death. 1999;138:549-54
Kawai C (*see* Nakamura et al). 1999;138:500-6
Kawaii C (*see* Nakamura et al). 1999;138:577-85
Kelsey SF. Patients with diabetes did better with coronary bypass graft surgery than with percutaneous transluminal coronary angioplasty: was this BARI finding real? 1999;18:S387-S393
Kennedy HL (*see* Goldstein et al). 1999;138:1158-65
Kennedy WJ (*see* Grayston et al). 1999;138:S545-S549
Kerber S (*see* Spiecker et al). 1999;138:518-24
Kereiakes DJ. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? 1999;138:S39-S46
Kereiakes DJ (*see* Tcheng et al). 1999;138:S33-S38
Keren G (*see* Kassirer et al). 1999;138:555-9
Kersten ME (*see* Murdock et al). 1999;138:151-5
Kessler D (*see* Ardehali et al). 1999;138:983-6
Keteyian SJ, Brawner CA, Schairer JR, Levine TB, Levine AB, Rogers FJ, Goldstein S. Effects of exercise training on chronotropic incompetence in patients with heart failure. 1999;138:233-40
Keul J (*see* Halle et al). 1999;138:309-12
Khaja F (*see* Ali et al). 1999;138:1133-9
Khan S, Trento A, Kass R, DeRobertis M, Sandhu M, Nessim S. Actual failure rates: a method of assessing tissue valve reoperation rates. 1999;138:108-13
Khattar RS (*see* Senior et al). 1999;138:163-8
Khaw K, Moreyra AE, Tannenbaum AK, Hosler MN, Brewer TJ, Agarwal JB. Improved detection of posterior myocardial wall ischemia with the 15-lead electrocardiogram. 1999;138:934-40
Khurana S (*see* Redle et al). 1999;138:144-50
Kiaii M (*see* McAlister et al). 1999;138:87-94
Kiefe CI (*see* Rosen et al). 1999;138:69-77
Kim JJ (*see* Lee et al). 1999;138:S60-S63
Kimura BJ (*see* Arbab-Zadeh et al). 1999;138:865-72
King TE (*see* Dangas et al). 1999;138:49-54
Kinoshita M (*see* Nakamura et al). 1999;138:500-6
Kinoshita M (*see* Nakamura et al). 1999;138:577-85
Kinoshita M (*see* Ueda et al). 1999;138:908-15
Kiowski W (*see* Brunner-La Rocca et al). 1999;138:654-62
Kirtchevsky D. Diet and atherosclerosis. 1999;138:S426-S430
Kisslo KB (*see* Wang et al). 1999;138:777-84
Kitabatake A (*see* Sato et al). 1999;138:560-6
Kitabatake A (*see* Nanbu et al). 1999;138:641-5
Klauss V (*see* Regar et al). 1999;138:1198-9 (Letter)
Klainman E (*see* Zafrir et al). 1999;138:1088-92
Kleiger RE (*see* Stein et al). 1999;138:567-76
Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. 1999;138:S263-S275
Klein AL, Canale MP, Rajagopalan N, White RD, Murray RD, Wahi S, Arheart KL, Thomas JD. Role of transesophageal echocardiography in assessing diastolic dysfunction in a large clinical practice: a 9-year experience. 1999;138:880-9
Klein HU (*see* Geller et al). 1999;138:987-93
Klimmeck S (*see* Schuchert et al). 1999;138:45-8
Klingbeil A (*see* Schlaich et al). 1999;138:810-17
Klootwijk P (*see* Moons et al). 1999;138:525-32
Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD). 1999;138:849-55
Knudsen K (see Christiansen et al). 1999;138:S491-S495
Kobashigawa JA (*see* Son et al). 1999;138:358-63
Kol A, Libby P. Molecular mediators of arterial inflammation: a role for microbial products? 1999;138:S450-S452
Kong DF. Steroids for restenosis: strike three! 1999;138:3-4 (Editorial)
Kong DF (*see* Alexander et al). 1999;138:175-90
Kong DF (*see* Tcheng et al). 1999;138:602-5 (Editorial)
Konstam MA (*see* Smith and Konstam). 1999;138:14-16 (Editorial)
Kormos RL (*see* Mankad et al). 1999;138:721-30
Korsten J (*see* Hoepp et al). 1999;138:941-9
Kosinski A (*see* Weintraub et al). 1999;138:S394-S399
Kostis JB (*see* Gregory et al). 1999;138:507-17
Koyama J, Owa M, Asakawa K, Hikita H, Ohkubo K, Ikeda S. Effect of distal stenosis of internal thoracic artery bypass grafts on longitudinal phasic blood flow velocity characteristics. 1999;138:468-76
Kramer PH (*see* Crouse and Kramer). 1999;138:19-20 (Editorial)
Kratzsch G (*see* Tebbe et al). 1999;138:S39-S44
Kraus W. Insulin resistance syndrome and cardiovascular disease: genetics and connections to skeletal muscle function. 1999;138:S413-S416
Kresowik T (*see* Rosen et al). 1999;138:69-77
Krespi PG (*see* Makris et al). 1999;138:922-5
Krespi P (*see* Hatzizacharias et al). 1999;138:241-6
Krucoff M (*see* Corbalán et al). 1999;138:533-9
Krumholz HM (*see* Vaccarino et al). 1999;138:835-42
Kuijer JPA (*see* Götte et al). 1999;138:1038-45
Kuipers EJ (*see* Kusters and Kuipers). 1999;138:S523-S527
Kukin ML, Freudenberger RS, Mannino MM, Kalman J, Steinmetz M, Buchholz-Varley C, Ocampo ON. Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. 1999;138:261-8
Kunz T (*see* Glunz et al). 1999;138:1111-7
Kuo C. Pathologic manifestation of *chlamydial* infection. 1999;138:S496-S499
Kuo C (*see* Campbell and Kuo). 1999;138:S517-S518
Kurogane H (*see* Tamai et al). 1999;138:968-75
Kusters J, Kuipers EJ. Helicobacter and atherosclerosis. 1999;138:S523-S527
Kvasnicka JH (*see* Flack et al). 1999;138:486-92
Kyriaki DK (*see* Makris et al). 1999;138:922-5
Kyriakidis MK (*see* Makris et al). 1999;138:922-5
Kyriakidis M (*see* Hatzizacharias et al). 1999;138:241-6

L

L'Abbate A. Recanalization versus reperfusion for myocardial survival and preservation of ventricular geometry. 1999;138:S89-S95
La Rosée K (*see* Hoepp et al). 1999;138:941-9
Lahiri A (*see* Senior et al). 1999;138:163-8
Laks H (*see* Ardehali et al). 1999;138:983-6
Lambrew CT (*see* Scirica et al). 1999;138:1065-72
Lange S (*see* Machraoui et al). 1999;138:663-9
Langrall MA (*see* Tcheng et al). 1999;138:S33-S38
Larson AC (*see* Pope et al). 1999;138:890-9
Latini R (*see* Oliva et al). 1999;138:247-53
Latini R (*see* Maggioni and Latini). 1999;138:S183-S187
Lau KW (*see* Hung et al). 1999;138:114-21
Lawson WT (*see* Pettis et al). 1999;138:765-70
Lécluse E (*see* Hamon et al). 1999;138:55-9
Lee CW, Chae JK, Lim HY, Hong MK, Kim JJ, Park SW, Park SJ. Prospective randomized trial of corticosteroids for the pre-

vention of restenosis after intracoronary stent implantation. 1999;138:S60-S63
Lee JJ (*see* Fung et al). 1999;138:696-704
Lee TH. Chest pain algorithms in the troponin era: time to integrate expertise. 1999;138:606-8 (Editorial)
Lehmann KG, Heath-Lange SJ, Ferris ST. Randomized comparison of hemostasis techniques after invasive cardiovascular procedures. 1999;138:1118-25
Leibrandt PN (*see* Pettis et al). 1999;138:765-70
Leinonen M, Saikku P. Interaction of *Chlamydia pneumoniae* infection with other risk factors of atherosclerosis. 1999;138:S504-S506
Lem V (*see* Lucas et al). 1999;138:618-24
Lemke B (*see* Machraoui et al). 1999;138:663-9
Lenderink T (*see* Moons et al). 1999;138:525-32
Leprince P, Fretz C, Dorent R, Boudifa A, Jourdan J, Youssoub JJ, Bors V, Nataf P, Pavie A, Gandjbakhch I. Posttransplantation cytotoxic immunoglobulin G is associated with a high rate of acute allograft dysfunctions in heart transplant recipients. 1999;138:586-92
Levine AB (*see* Keteyian et al). 1999;138:233-40
Levine TB (*see* Keteyian et al). 1999;138:233-40
Lewin HC (*see* Kang et al). 1999;138:1025-32
Lewis AB. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy. 1999;138:334-8
Libby P (*see* Kol and Libby). 1999;138:S450-S452
Liberty IF (*see* Katz et al). 1999;138:32-8
Lim HY (*see* Lee et al). 1999;138:S60-63
Limbourg P (*see* Glunz et al). 1999;138:1111-7
Lincoff AM (*see* Gilchrist et al). 1999;138:976-82
Lindbloom EJ, Stevermer JJ. Cardiac troponin I as a marker for AMI. 1999;138:798 (Letter)
Linn S (*see* Roguin et al). 1999;138:326-33
Liotta AA (*see* Michelucci et al). 1999;138:128-32
Lissel C (*see* Suedkamp et al). 1999;138:269-72
Liu K (*see* Flack et al). 1999;138:856-64
Lo PH (*see* Hung et al). 1999;138:114-21
London GM, Guerin AP. Influence of arterial pulse and reflected waves on blood pressure and cardiac function. 1999;138: S220-S224
Lorch G (*see* Fung et al). 1999;138:696-704
Losordo DW, Vale PR, Isner JM. Gene therapy for myocardial angiogenesis. 1999;138:S132-S141
Lotan C (*see* Rozenman et al). 1999;138:441-5
Lovett EG (*see* Pope et al). 1999;138:890-9
Low MD (*see* Franzini et al). 1999;138:414-21
Lower JE (*see* Hochrein et al). 1999;138:791-7
Lucas C, Warner Stevenson L, Johnson W, Hartley H, Hamilton MA, Walden J, Lem V, Eagen-Bengsten E. The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival. 1999;138:618-24
Lucke JC (*see* Hochrein et al). 1999;138:791-7
Lucreziotti S (*see* Ferrario et al). 1999;138:S121-S125

M

Maatouk F (*see* Jarrar et al). 1999;138:950-4
Macaya C (*see* Escaned et al). 1999;138:675-80
Machraoui A, Germing A, von Dryander S, Lange S, Jäger D, Lemke B, Barmeyer J. Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study. 1999;138:663-9
Maclure M (*see* Mukamal et al). 1999;138:926-33
Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. 1999;138: S317-S326
Madsen AS (*see* Christiansen et al). 1999;138:S491-S495
Maggioni AP, Latini R. How to use ACE inhibitors, β-blockers, and newer therapies in AMI. 1999;138:S183-S187
Maggioni AP (*see* Oliva et al). 1999;138:247-53
Maggioni AP (*see* Fresco et al). 1999;138:1058-64
Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I Trial. 1999;138:493-9
Mair J (*see* Missov and Mair). 1999;138:95-9
Makris T (*see* Hatzizacharias et al). 1999;138:241-6
Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Kyriaki DK, Chronakis EV, Anastasiadis G, Triposkiadis FK, Kyriakidis MK. Elevated plasma immunoreactive leptin levels preexist in healthy offspring of patients with essential hypertension. 1999;138:922-5
Malhotra S (*see* Hochman et al). 1999;138:313-8
Malinow R (*see* Garg et al). 1999;138:1082-7
Malmberg K, McGuire DK. Diabetes and acute myocardial infarction: the role of insulin therapy. 1999;138:S381-S386
Maly FE (*see* Brunner-La Rocca et al). 1999;138:654-62
Manda V (*see* Twidale et al). 1999;138:1166-75
Mandarino WA (*see* Mankad et al). 1999;138:721-30
Mankad S, Murali S, Kormos RL, Mandarino WA, Gorscan III J. Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients. 1999;138:721-30
Manley SE (*see* Adler et al). 1999;138:S353-S359
Mannino MM (*see* Kukin et al). 1999;138:261-8
Manolio TA (*see* Flack et al). 1999;138:486-92
Marciano F (*see* Bonaduce et al). 1999;138:273-84
Marcus JT (*see* Götte et al). 1999;138:1038-45
Mark DB (*see* Hlatky et al). 1999;138:376-83
Markiewicz W (*see* Roguin et al). 1999;138:326-33
Marmur JD (*see* Dangas et al). 1999;138:49-54
Martin JS (*see* Fung et al). 1999;138:696-704
Martínez A (*see* Morales et al). 1999;138:291-8
Marwick TH (*see* Pasquet et al). 1999;138:753-8
Marzan R (*see* Redle et al). 1999;138:144-50
Mascelli MA (*see* Tcheng et al). 1999;138:S33-S38
Massie BM (*see* Teerlink and Massie). 1999;138:193-7 (Editorial)
Massie BM (*see* Burnett et al). 1999;138:1140-8
Massie BM (*see* Baker et al). 1999;138:826-34
Massie BM (*see* Bello et al). 1999;138:100-7
Massie BM (*see* Heidenreich et al). 1999;138:633-40
Mathew V, Garratt KN, Holmes Jr DR. Clinical outcome after multivessel coronary stent implantation. 1999;138:1105-10
Matturri M (*see* Guazzi et al). 1999;138:460-7
Mauri F (*see* Oliva et al). Trial 1999;138:247-53
Maynard C (*see* Pettis et al). 1999;138:765-70
Maynard C (*see* Ritchie et al). 1999;138:437-40
McAlister FA, Teo KK, Taher M, Montague TJ, Humen D, Cheung L, Kiaii M, Yim R, Armstrong PW. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. 1999;138:87-94
McCargar PA (*see* Mehta et al). 1999;138:688-95
McCormick MT (*see* Vesely et al). 1999;138:625-32
McCullough PA (*see* Redle et al). 1999;138:144-50
McDonagh TA (*see* Murdoch et al). 1999;138:1126-32
McGhie AI (*see* Franzini et al). 1999;138:414-21
McGovern PG (*see* Goff et al). 1999;138:1046-57
McGuire DK (*see* Malmberg and McGuire). 1999;138:S381-S386
McGuire DK (*see* Abraira and McGuire). 1999;138:S360-S365
McGuire DK, Granger CB. Diabetes and ischemic heart disease. 1999;138:S366-S375
McGuire DK, Califf RM. Diabetes and cardiovascular disease: current opinions and future directions. 1999;138:S327-S329
McInnes GT. Integrated approaches to management of hypertension: promoting treatment acceptance. 1999;138:S252-S255
McIntyre KM (*see* Knight et al). 1999;138:849-55
McKenna WJ (*see* O'Connor et al). 1999;138:78-86
McKenney JM (*see* Burnett et al). 1999;138:1140-8

McNulty SE (*see* O'Connor et al). 1999;138:78-86
McPherson C (*see* Qamar et al). 1999;138:705-9
Mehlhorn U (*see* Suedkamp et al). 1999;138:269-72
Mehta RH, Stalhandske EJ, McCargar PA, Ruane TJ, Eagle KA. Elderly patients at highest risk with acute myocardial infarction are more frequently transferred from community hospitals to tertiary centers: reality or myth? 1999;138:688-95
Meij SH (*see* Moons et al). 1999;138:525-32
Meinertz T (*see* Schuchert et al). 1999;138:45-8
Meisner C (*see* Schroeder et al). 1999;138:731-9
Melton IC, Wood MA, Ellenbogen KA. Radiofrequency atrioventricular junction ablation for atrial fibrillation: how can we make it better? 1999;138:1016-8
Mena I (*see* Oudiz et al). 1999;138:369-75
Mendes LA, Picard MH, Dec GW, Hartz VL, Palacios IF, Davidoff R. Ventricular remodeling in active myocarditis. 1999;138:303-8
Méndez M (*see* Morales et al). 1999;138:291-8
Mercé J, Sagristà-Sauleda J, Permanyer-Miralda G, Evangelista A, Soler-Soler J. Correlation between clinical and Doppler echocardiographic findings in patients with moderate and large pericardial effusion: implications for the diagnosis of cardiac tamponade. 1999;138:759-64
Mereuta A (*see* Rozenman et al). 1999;138:441-5
Messineo FC (*see* Burnett et al). 1999;138:1140-8
Meyer J (*see* Spiecker et al). 1999;138:518-24
Michels R (*see* Spiecker et al). 1999;138:518-24
Michelucci A, Antonucci E,Conti AA, Liotta AA, Fedi S, Padeletti L, Porciani MC, Prisco D, Abbate R, Gensini GF. Electrophysiologic procedures and activation of the hemostatic system. 1999;138:128-32
Miller B (*see* Pescatello et al). 1999;138:916-21
Miller H (*see* Kassirer et al). 1999;138:555-9
Miller TR (*see* Rinder et al). 1999;138:169-74
Misra B (*see* Cohen et al). 1999;138:1019-24
Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T 1999;138:95-9
Mittleman MA (*see* Mukamal et al). 1999;138:926-33
Miyatake K (*see* Hongo et al). 1999;138:345-50
Mizuno O (*see* Ikeda et al). 1999;138:1199 (Letter)
Moe GW (*see* Parker et al). 1999;138:843-8
Mogun H (*see* Knight et al). 1999;138:849-55
Moliterno DJ (*see* Asher et al). 1999;138:1073-81
Moliterno DJ (*see* Scirica et al). 1999;138:1065-72
Molnar J (*see* Aytemir and Yap). 1999;138:385-6 (Letter reply)
Montague TJ (*see* McAlister et al). 1999;138:87-94
Montemayor T (*see* Morales et al). 1999;138:291-8
Moons KGM, Klootwijk P, Meij SH, van Es GA, Baardman T, Lenderink T, van den Brand M, Habbema DF, Grobbee DE, Simoons ML. Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial. 1999;138:525-32
Moore JA (*see* Cooper et al). 1999;38:430-6
Morales FJ, Martínez A, Méndez M, Agarrado A,Ortega F, Fernández-Guerra J, Montemayor T, Burgos J. A shuttle walk test for assessment of functional capacity in chronic heart failure. 1999;138:291-8
Morbini P (*see* Arbustini et al). 1999;138:S55-S60
Moreyra AE (*see* Khaw et al). 1999;138:934-40
Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida J. Can β-blocker therapy be withdrawn from patients with dilated cardiomyopathy? 1999;138:456-9
Morimoto SI (*see* Uemura et al). 1999;138:299-302
Morise AP. Comparison of the Diamond-Forrester method and a new score to estimate the pretest probability of coronary disease before exercise testing. 1999;138:740-52
Morton JJ (*see* Murdoch et al). 1999;138:1126-32
Moschi G (*see* Antoniucci et al). 1999;138:S147-S152
Moschi G (*see* Antoniucci et al). 1999;138:670-4
Moss AJ (*see* Nakamura et al). 1999;138:577-85
Moss AJ (*see* Nakamura et al). 1999;138:500-6
Moses J, Moussa I. Do new devices add to the results of PTCA in acute myocardial infarction? 1999;138:S158-S163
Mosseri M (*see* Rozenman et al). 1999;138:441-5
Motheral BR (*see* Roe et al). 1999;138:818-25
Moussa I (*see* Moses and Moussa). 1999;138:S158-S163
Moyssakis IE (*see* Rallidis et al). 1999;138:351-7
Mozas P (*see* Civeira et al). 1999;138:156-62
Mügge A (*see* Blessing et al). 1999;138:1199 (Letter reply)
Muhlbaier LH (*see* Rosen et al). 1999;138:69-77
Muhlestein JB. Animal models of *chlamydia* and atherosclerosis. 1999;138:S514-S515
Muhlestein JB (*see* Gilchrist et al). 1999;138:976-82
Mukamal KJ, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Lack of effect of recent alcohol consumption on the course of acute myocardial infarction. 1999;138:926-33
Muller JE (*see* Mukamal et al). 1999;138:926-33
Murali S (*see* Mankad et al). 1999;138:721-30
Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. 1999;138:1126-32
Murdock AK (*see* Murdock et al). 1999;138:151-5
Murdock DK, Murdock AK, Murdock RW, Olson KJ, Frane AM, Kersten ME, Joyce DM, Gantner SE. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. 1999; 138:151-5
Murdock RW (*see* Murdock et al). 1999;138:151-5
Murray RD (*see* Klein et al). 1999;138:880-9
Myers RBH, Spodick DH. Constrictive pericarditis: clinical and pathophysiologic characteristics. 1999;138:219-32
Mygind P (*see* Christiansen et al). 1999;138:S491-S495

N

Nakakoshi T (*see* Nanbu et al). 1999;138:641-5
Nakamura M (*see* Sakatani et al). 1999;138:962-7
Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. 1999;138:577-85
Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Ethnicity and long-term outcome after an acute coronary event. 1999;138:500-6
Nanbu T, Nakakoshi T, Yonezawa K, Kitabatake A. Myocardial high-energy phosphate metabolism in patients with stable chronic dilated cardiomyopathy under a dobutamine-induced prolonged mild workload. 1999;138:641-5
Narahara KA (*see* Oudiz et al). 1999;138:369-75
Nash IS, Curtis LH, Rubin H. Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization. 1999;138:422-9
Nassar H (*see* Rozenman et al). 1999;138:441-5
Nataf P (*see* Leprince et al). 1999;138:586-92
Nazzal C (*see* Corbalán et al). 1999;138:533-9
Neil HAW (*see* Adler et al). 1999;138:S353-S359
Nessim S (*see* Khan et al). 1999;138:108-13
Newby DE (*see* Northridge et al). 1999;138:1149-57
Newby LK. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial. 1999;138:210-8
Newman AR (*see* Hillegass et al). 1999;138:S24-S32
Nicholson AC, Hajjar DP. Viral activation of the coagulation cascade. 1999;138:S461-S464

Nicolai E (*see* Bonaduce et al). 1999;138:273-84
Nicoletti A, Caligiuri G, Paulssön G, Hansson GK. Functionality of specific immunity in atherosclerosis. 1999;138:S438-S443
Nicolis E (*see* Oliva et al). 1999;138:247-53
Nicolucci A (*see* Fresco et al). 1999;138:1058-64
Nieto FJ. Viruses and atherosclerosis: a critical review of the epidemiologic evidence. 1999;138:S453-S460
Nihoyannopoulos P (*see* Tousoulis et al). 1999;138:873-9
Nihoyannopoulos P (*see* Rallidis et al). 1999;138:351-7
Nishikawa H (*see* Tamai et al). 1999;138:968-75
Nixdorff U (*see* Spiecker et al). 1999;138:518-24
Norrie J (*see* Northridge et al). 1999;138:1149-57
Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. 1999;138:1149-57
Nunez E (*see* Silva et al). 1999;138:446-55
Nuschbacher A (*see* Tarasoutchi et al). 1999;138:477-85

O

O'Connor CM, Gattis WA, Gheorghiade M, Granger CB, Gilbert J, McKenney JM, Messineo FC, Burnett JC, Katz SD, Elkayam U, Kasper EK, Goldstein S, Cody RJ, Massie BM. A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S Ecadotril Pilot Safety Study. 1999;138:1140-8
O'Connor CM, Gattis WA, Uretsky BF, Adams Jr KF, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). 1999;138:78-86
O'Connor CM (*see* Orloff et al). 1999;138:S406-412
O'Connor CM (*see* Del Carlo and O'Connor). 1999;138:646-53
O'Connor CM (*see* Velazquez et al). 1999;138:1009-11
O'Connor S. Fulfillment of Koch's postulates and the causes of atherosclerosis. 1999;138:S550-S551
O'Dowd KJ (*see* Gregory et al). 1999;138:507-17
O'Laughlin MP, Harrison JK. ASDOS closures: congratulations and technical observations. 1999;138:808-9 (Editorial)
O'Neal Humphries J (*see* Rosen et al). 1999;138:69-77
O'Neill WW (*see* Redle et al). 1999;138:144-50
O'Neill WW (*see* Ajluni et al). 1999;138:1012-3
Oberhoff M (*see* Schroeder et al). 1999;138:731-9
Ocampo ON (*see* Kukin et al). 1999;138:261-8
Offenbacher S (*see* Beck et al). 1999;138:S529-S533
Ohkubo K (*see* Koyama et al). 1999;138:468-76
Ohlstein EH (*see* Brooks et al). 1999;138:S246-S251
Oliva F, Latini R, Politi A, Staszewsky L, Maggioni AP, Nicolis E, Mauri F. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial. 1999;138:247-53
Olson KJ (*see* Murdock et al). 1999;138:151-5
Oral H, Armstrong WF, Bach DS. Preserved diagnostic utility of dobutamine stress echocardiography in pacemaker-dependent patients with absolute chronotropic incompetence. 1999;138:364-8
Orloff DG, Blazing MA, O'Connor CM. Atherosclerotic disease in non–insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies. 1999;138:S406-S412
Ortega F (*see* Morales et al). 1999;138:291-8
Osganian SK (*see* Goff et al). 1999;138:1046-57
Ossen R (*see* Schroeder et al). 1999;138:731-9
Oudiz RJ, Smith DE, Pollak AJ, Mena I, Shapiro SM, Ginzton LE, Narahara KA. Nitrateenhanced thallium 201 single-photon emission computed tomography imaging in hibernating myocardium. 1999;138:369-75
Overton RM (*see* Vesely et al). 1999;138:625-32
Ovsysheher I (*see* Katz et al). 1999;138:32-8
Owa A (*see* Koyama et al). 1999;138:468-76
Ozawa K (*see* Ueda et al). 1999;138:908-15

P

Pacileo G (*see* Calabró et al). 1999;138:955-61
Padeletti L (*see* Michelucci et al). 1999;138:128-32
Palacioos IF (*see* Mendes et al). 1999;138:303-8
Palazzo AM (*see* Hochman et al). 1999;138:313-8
Pandalino M (*see* Pessotto et al). 1999;138:1184-95
Pangerl A (*see* Bhatt et al). 1999;138:785-90
Pankow J (*see* Beck et al). 1999;138:S529-S533
Park SJ (*see* Lee et al). 1999;138:S60-S63
Park SW. (*see* Lee et al). 1999;138:S60-S63
Parker AB, Azevedo ER, Baird MG, Smith SJ, Arnold MO, Humen DP, Moe GW, Parker JO, Butt RW, Parker JD. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. 1999;138:843-8
Parker JD (*see* Parker et al). 1999;138:843-8
Parker JO (*see* Parker et al). 1999;138:843-8
Parks JR (*see* Vesely et al). 1999;138:625-32
Parmley WW. Cost-effectiveness of reperfusion strategies. 1999;138:S142-S146
Pasquet A, Yamada E, Armstrong G, Beachler L, Marwick TH. Influence of dobutamine or exercise stress on the results of pulsed-wave Doppler assessment of myocardial velocity. 1999;138:753-8
Patel CR (*see* Siwik et al). 1999;138:771-6
Paulssön G (*see* Nicoletti et al). 1999;138:S438-S433
Pavie A (*see* Leprince et al). 1999;138:586-92
Pearlman AS (*see* Rakowski and Pearlman). 1999;138:609-11 (Editorial)
Pedersen TR. Statin trials and goals of cholesterol-lowering therapy after AMI. 1999;138:S177-S182
Penny WF (*see* Arbab-Zadeh et al). 1999;138:865-72
Perchinka H (*see* Wick et al). 1999;138:S444-S449
Percoco G (*see* Ferrari et al). 1999;138:S61-S68
Permanyer-Miralda G (*see* Mercé et al). 1999;138:759-64
Perry RC (*see* Clark and Perry). 1999;138:S330-S333
Pescatello LS, Miller B, Danias PG, Werner M, Hess M, Baker C, De Souza MJ. Dynamic exercise normalizes resting blood pressure in mildly hypertensive premenopausal women. 1999;138:916-21
Pessotto R, Padalino M, Rubino M, Kadoba K, Büchler JR, Van Praagh R. Straddling tricuspid valve as a sign of ventriculoatrial malalignment: a morphometric study of 19 postmortem cases. 1999;138:1184-95
Peters RW (*see* Cooklin et al). 1999;138:133-6
Peterson ED (*see* Rosen et al). 1999;138:69-77
Petretta M (*see* Bonaduce et al). 1999;138:273-84
Pettinger M (*see* Garg et al). 1999;138:1082-7
Pettis KS, Savona MR, Leibrandt PN, Maynard C, Lawson WT, Gates KB, Wagner GS. Evaluation of the efficacy of hand-held computer screens for cardiologists' interpretations of 12-lead electrocardiograms. 1999;138:765-70
Pfisterer M (*see* Hasdai et al). 1999;138:21-31
Pfohl M (*see* Schroeder et al). 1999;138:731-9
Picard MH (*see* Mendes et al). 1999;138:303-8
Pisacane C (*see* Calabró et al). 1999;138:955-61
Pitt B (*see* Hlatky et al). 1999;138:376-83
Plotkin S (*see* Dodet and Plotkin). 1999;138:S417-S418
Plotkin S. Conclusions. 1999;138:S560
Plotkin S. Cytomegalovirus vaccine. 1999;138:S484-S487
Pocoví M (*see* Civeira et al). 1999;138:156-62
Politi A (*see* Oliva et al). 1999;138:247-53
Pollak AJ (*see* Oudiz et al). 1999;138:369-75

Pomerantezeff P (*see* Tarasoutchi et al). 1999;138:477-85
Pontone G (*see* Guazzi et al). 1999;138:460-7
Pontone G (*see* Guazzi et al). 1999;138:254-60
Poole-Wilson PA. Tailored treatment for heart failure: an emerging concept. 1999;138:1005-6
Pope III CA, Verrier RL, Lovett EG, Larson AC, Raizenne ME, Kanner RE, Schwartz J, Villegas M, Gold DR, Dockery DW. Heart rate variability associated with particulate air pollution. 1999;138:890-9
Popovic AD. Old and new paradigms on diastolic function in acute myocardial infarction. 1999;138:S84-S88
Porath A (*see* Katz et al). 1999;138:32-8
Porciani MC (*see* Michelucci et al). 1999;138:128-32
Posada IS, Barriales V. Alternate-day dosing of aspirin in artrial fibrillation. 1999;138:137-43
Potier JC (*see* Hamon et al). 1999;138:55-9
Poulsen SH, Jensen SE, Egstrup K. Effects of long-term adrenergic β-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. 1999;138:710-20
Pracyk JB, Drennan S, Tcheng JE. Hemostasis of the femoral vasculature: shouldn't we have an answer by now? 1999;138:1014-5
Prati F (*see* Arbustini et al). 1999;138:S55-S60
Prieto JC (*see* Corbalán et al). 1999;138:533-9
Prisco D (*see* Michelucci et al). 1999;138:128-32
Pritchett ELC (*see* Al-Khatib and Pritchett). 1999;138:403-13
Pritchett ELC, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. 1999;138:994-7
Prochorov V (*see* Kassirer et al). 1999;138:555-9
Prystowsky EN (*see* Katz et al). 1999;138:32-8
Puzo J (*see* Civeira et al). 1999;138:156-62
Pyles JM (*see* Wilensky et al). 1999;138:319-25

Q

Qamar A, McPherson C, Babb J, Bernstein L, Werdmann M, Yasick D, Zarich S. The Goldman algorithm revisisted: Prospective evaluation of a computer-derived algorithm versus unaided physician judgment in suspected acute myocardial infarction. 1999;138:705-9
Quinn TC, Gaydos CA. In vitro infection and pathogenesis of *Chlamydia pneumoniae* in endovascular cells. 1999;138:S507-S511

R

Rabbani LE (*see* Scirica et al). 1999;138:1065-72
Raco DL (*see* Hillegass et al). 1999;138:S24-S32
Radord MJ (*see* Vaccarino et al). 1999;138:835-42
Rainer de Vivie E (*see* Suedkamp et al). 1999;138:269-72
Raizenne ME (*see* Pope et al). 1999;138:890-9
Rajagopalan N (*see* Klein et al). 1999;138:880-9
Rakowski H, Pearlman AS. Preventing perioperative stroke: look, but don't touch! 1999;138:609-11 (Editorial)
Rallidis L (*see* Tousoulis et al). 1999;138:873-9
Rallidis LS, Moyssakis IE, Ikonomidis I, Nihoyannopoulos P. Natural history of early aortic paraprosthetic regurgitation: a five-year follow-up. 1999;138:351-7
Ramee SR (*see* Silva et al). 1999;138:446-55
Rao MAE (*see* Bonaduce et al). 1999;138:273-84
Rao SV, Bethel MA, Feinglos MN. Treatment of diabetes mellitus: implications of the use of oral agents. 1999;138:S334-S338
Redle JD, Khurana S, Marzan R, McCullough PA, Stewart JR, Westveer DC, O'Neill WW, Bassett JS, Tepe NA, Frumin HI. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery. 1999;138:144-50
Reed III JF (*see* Kaufmann et al). 1999;138:549-54
Reeder GS (*see* Hlatky et al). 1999;138:376-83
Reek S (*see* Geller et al). 1999;138:987-93
Regar E, Spes C, Klauss V. Observer-related variability in IVUS measurements after stenting. 1999;138:1198-9 (Letter)
Repetto A (*see* Ferrario et al). 1999;138:S121-S125
Rich MW (*see* Roe et al). 1999;138:818-25
Rich MW. Multidisciplinary interventions for the management of heart failure: where do we stand? 1999;138:599-601 (Editorial)
Richardeau Y (*see* Hamon et al). 1999;138:55-9
Richer-Cornish K (*see* Ali et al). 1999;138:1133-9
Rihal CS, Holmes Jr DR. Transradial cardiac catheterization: is femoral access obsolete? 1999;138:392-3 (Editorial)
Rinder MR, Miller TR, Ehsani AA. Effects of endurance exercise training on left ventricular systolic performance and ventriculoarterial coupling in patients with coronary artery disease. 1999;138:169-74
Ritchie JL, Maynard C, Every NR, Chapko MK. Coronary artery stent outcomes in a Medicare population: less emergency bypass surgery and lower mortality rates in patients with stents. 1999;138:437-40
Rodgers JK (*see* Kaufmann et al). 1999;138:549-54
Roe CM, Motheral BR, Teitelbaum F, Rich MW. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. 1999;138:818-25
Rogers FJ (*see* Keteyian et al). 1999;138:233-40
Rogers WJ (*see* Hlatky et al). 1999;138:376-83
Roguin A, Grenadier E, Linn S, Markiewicz W, Beyar R. Continued expansion of the nitinol self-expanding coronary stent: angiographic analysis and 1-year clinical follow-up. 1999;138:326-33
Rohads GG (*see* Gregory et al). 1999;138:507-17
Roivainen M. Enteroviruses and myocardial infarction. 1999;138:S479-S483
Rooney E (*see* Northridge et al). 1999;138:1149-57
Rosamond WD (*see* White et al). 1999;138:540-8
Rosen A (*see* Hlatky et al). 1999;138:376-83
Rosen AB, O'Neal Humphries J, Muhlbaier LH, Kiefe CI, Kresowik T, Peterson ED. Effect of clinical factors on length of stay after coronary artery bypass surgery: results of the Cooperative Cardiovascular Project. 1999;138:69-77
Ross R. Atherosclerosis is an inflammatory disease. 1999;138:S419-S420
Roth A (*see* Kassirer et al). 1999;138:555-9
Rottman JN (*see* Stein et al). 1999;138:567-76
Rozenman Y, Mereuta A, Schechter D, Mosseri M, Lotan C, Nassar H, Weiss AT, Hasin Y, Chisin R, Gotsman MS. Long-term outcome of patients with very long stents for treatment of diffuse coronary disease. 1999;138:441-5
Ruane TJ (*see* Mehta et al). 1999;138:688-95
Rubin H (*see* Nash et al). 1999;138:422-9
Rubino M (*see* Pessotto et al). 1999;138:1184-95
Ruffolo Jr RR (*see* Brooks et al). 1999;138:S246-S251
Ruggerio CM (*see* Heidenreich et al). 1999;138:633-40
Russo RJ (*see* Arbab-Zadeh et al). 1999;138:865-72
Ryan TJ (*see* Hlatky et al). 1999;138:376-83
Ryan TJ, Ryan Jr TJ, Jacobs AK. Primary PTCA versus thrombolytic therapy: an evidence-based summary. 1999;138:S96-S104
Ryan Jr TJ (*see* Ryan et al). 1999;138:S96-S104
Ryan T (*see* Wang et al). 1999;138:777-84
Rybicki BA (*see* Ali et al). 1999;138:1133-9

S

Sabatier R (*see* Hamon et al). 1999;138:55-9
Sabbah HN (*see* Ali et al). 1999;138:1133-9
Sagristà-Sauleda J (*see* Mercé et al). 1999;138:759-64
Saikku P (*see* Leinonen and Saikku). 1999;138:S504-S506
Saikku P. Epidemiology of *Chlamydia pneumoniae* in atherosclerosis. 1999;138:S500-S503

Sakai K (*see* Tamai et al). 1999;138:968-75
Sakatani H, Degawa T, Nakamura M, Yamaguchi T. Intracoronary surface changes after Palmaz-Schatz stent implantation: serial observations with coronary angioscopy. 1999;138:962-7
Sakurai M (*see* Sato et al). 1999;138:560-6
Saloux E (*see* Hamon et al). 1999;138:55-9
Sanderson JE. Confusion in geography. 1999;138:1196 (Letter reply)
Sandhu M (*see* Khan et al). 1999;138:108-13
Sangiorgi G, Taylor AJ, Farb A, Carter AJ, Edwards WD, Holmes DR, Schwartz RS, Virmani R. Histopathology of postpercutaneous transluminal coronary angioplasty remodeling in human coronary arteries. 1999;138:681-7
Santoro E (*see* Fresco et al). 1999;138:1058-64
Santoro GM (*see* Antoniucci et al). 1999;138:670-4
Santoro GM, Buonamici P. Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction. 1999;138:S126-S131
Sapp SK (*see* Scirica et al). 1999;138:1065-72
Sato M, Sakurai M, Yotsukura A, Betsuyaku T, Ito T, Yoshida I,Kitabatake A. Diastolic potentials in verapamil-sensitive ventricular tachycardia: true potentials or bystanders of the reentry circuits? 1999;138:560-6
Savona MR (*see* Pettis et al). 1999;138:765-70
Scarborough RM. Development of eptifibatide. 1999;138:1093-1104
Schairer JR (*see* Keteyian et al). 1999;138:233-40
Schechter D (*see* Rozenman et al). 1999;138:441-5
Scherer J (*see* Fung et al). 1999;138:696-704
Schiele R (*see* Glunz et al). 1999;138:1111-7
Schlaich MP, Klingbeil A, Hilders K, Schobel HP, Schmieder RE. Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. 1999;138:810-17
Schmieder RE (*see* Schlaich et al). 1999;138:810-17
Schnabel P (*see* Hoepp et al). 1999;138:941-9
Schneider CA (*see* Hoepp et al). 1999;138:941-9
Schobel HP (*see* Schlaich et al). 1999;138:810-17
Schocken DD (*see* Vesely et al). 1999;138:625-32
Schoenman G (*see* Kassirer et al). 1999;138:555-9
Scholz J (*see* Schuchert et al). 1999;138:45-8
Schroeder S, Enderle MD, Ossen R, Meisner C, Baumbach A, Pfohl M, Herdeg C, Oberhoff M, Haering HU, Karsch KR. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. 1999;138:731-9
Schuchert A, Hamm C, Scholz J, Klimmeck S, Goldmann B, Meinertz T. Prehospital testing for troponin T in patients with suspected acute myocardial infarction. 1999;138:45-8
Schulman KA (*see* Sheifer and Schulman). 1999;138:396-9 (Editorial)
Schuster S (*see* Glunz et al). 1999;138:1111-7
Schwartz J (*see* Pope et al). 1999;138:890-9
Schwartz RS (*see* Sangiorgi et al). 1999;138:681-7
Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Cannon CP. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. 1999;138:1065-72
Seabra-Gomes R (*see* Spiecker et al). 1999;138:518-24
Seidl K (*see* Glunz et al). 1999;138:1111-7
Senges J (*see* Glunz et al). 1999;138:1111-7
Senior R, Soman P, Khattar RS, Lahiri A. Improved endocardial visualization with second harmonic imaging compared with fundamental two-dimensional echocardiographic imaging. 1999;138:163-8
Shah M (*see* Alexander et al). 1999;138:175-90
Shah NB (*see* Bello et al). 1999;138:100-7
Shapira I (*see* Kassirer et al). 1999;138:555-9
Shapiro SM (*see* Oudiz et al). 1999;138:369-75
Sharkey SW (*see* Apple and Sharkey). 1999;138:798 (Letter reply)
Sharma SK (*see* Dangas et al). 1999;138:49-54
Shaw LJ (*see* Kang et al). 1999;138:1025-32
Sheiban I (*see* Briguori et al). 1999;138:64-8
Sheifer SE, Schulman KA. Racial differences in the use of invasive cardiac procedures: a continuous quality improvement approach. 1999;138:396-9 (Editorial)
Sherman SE, D'Agostino RB, Silbershatz H, Kannel WB. Comparison of past versus recent physical activity in the prevention of premature death and coronary artery disease. 1999; 138:900-7
Sherwood JB (*see* Mukamal et al). 1999;138:926-33
Shimada K (*see* Ikeda et al). 1999;138:1199 (Letter)
Shimizu K (*see* Morimoto et al). 1999;138:456-9
Shorofsky SR (*see* Cooklin et al). 1999;138:133-6
Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. 1999;138:S238-S245
Sias TM, Watson DD, Beller GA. Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? 1999;138:206-9
Silbershatz H (*see* Sherman et al). 1999;138:900-7
Silva JA, Ramee SR, White CJ, Collins TJ, Jenkins JS, Nunez E, Zhang S, Jain SP. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. 1999;138:446-55
Silver MA. Intermittent inotropes for advanced heart failure: inquiring minds want to know. 1999;138:191-2 (Editorial)
Sim MJ (*see* Hochman et al). 1999;138:313-8
Simons-Morton DG (*see* Goff et al). 1999;138:1046-57
Simoons ML (*see* Mahaffey et al). 1999;138;493-9
Simoons ML (*see* Moons et al). 1999;138:525-32
Simpson Jr RJ (*see* Jollis et al). 1999;138:S376-S380
Singh S (*see* Kalra et al). 1999;138:339-44
Siwik ES, Spector ML, Patel CR, Zahka KG. Costs and cost-effectiveness of routine transesophageal echocardiography in congenital heart surgery. 1999;138:771-6
Sloan MA (*see* Mahaffey et al). 1999;138;493-9
Smith DE (*see* Oudiz et al). 1999;138:369-75
Smith HC (*see* Hlatky et al). 1999;138:376-83
Smith JJ, Konstam MA. Heart failure: a case for subspecialized care management. 1999;138:14-16 (Editorial)
Smith Jr SC (*see* Jollis et al). 1999;138:S376-S380
Smith SJ (*see* Parker et al). 1999;138:843-8
Soler-Soler J (*see* Mercé et al). 1999;138:759-64
Soman P (*see* Senior et al). 1999;138:163-8
Somberg JC (*see* Aytemir and Yap). 1999;138:385-6 (Letter reply)
Son R, Tobis JM, Teatman LA, Johnson JA, Wener LS, Kobashigawa JA. Does use of intravascular ultrasound accelerate arteriopathy in heart transplant recipients? 1999;138:358-63
Sone T (*see* Tamai et al). 1999;138:968-75
Sparks L (*see* Twidale et al). 1999;138:1166-75
Specchia G (*see* Arbustini et al). 1999;138:S55-S60
Spector ML (*see* Siwik et al). 1999;138:771-6
Spes C (*see* Regar et al). 1999;138:1198-9 (Letter)
Spiecker M, Windeler J, Vermeer F, Michels R, Seabra-Gomes R, vom Dahl J, Kerber S, Verheugt FWA, Westerhof PW, Bär FW, Nixdorff U, Barth H, Hopkins GR, von Fisenne MJM, Meyer J. Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI Trial. 1999;138:518-24
Spitzer S (*see* Zafrir et al). 1999;138:1088-92
Spodick DH (*see* Myers et al). 1999;138:219-32
Stafford RS (*see* Cohen et al). 1999;138:1019-24
Stahl JN, Zellner C, Chou TM. Telemedicine in cardiology. 1999;138:1200 (Letter)
Stalhandske EJ (*see* Mehta et al). 1999;138:688-95
Staszewsky L (*see* Oliva et al). Trial 1999;138:247-53
Stavroulakis GA (*see* Makris et al). 1999;138:922-5
Stein PK, Ehsani AA, Domitrovich PP, Kleiger RE, Rottman JN. Effect of exercise training on heart rate variability in healthy older adults. 1999;138:567-76
Steinmetz M (*see* Kukin et al). 1999;138:261-8

Stevermer JJ (*see* Lindbloom and Steverner). 1999;138:798 (Letter)
Stewart JR (*see* Redle et al). 1999;138:144-50
Stiles GL (*see* Tilley and Stiles). 1999;138:390-1 (Editorial)
Stock-Novack D (*see* Fung et al). 1999;138:696-704
Stone PH, Godleski JJ. First steps toward understanding the pathophysiologic link between air pollution and cardiac mortality. 1999;138:804-7 (Editorial)
Stoynov MY (*see* Dangas et al). 1999;138:49-54
Sturm M (*see* Blessing et al). 1999;138:1199 (Letter reply)
Suedkamp M, Lissel C, Eiffert H, Flesch M, Boehm M, Mehlhorn U, Thomssen R, Rainer de Vivie E. Cardiac myocytes of hearts from patients with end-stage dilated cardiomyopathy do not contain Borrelia burgdorferi DNA 1999;138:269-72
Sulkes J (*see* Zafrir et al). 1999;138:1088-92
Sussman EJ (*see* Kaufmann et al). 1999;138:549-54
Suzuki S (*see* Tamai et al). 1999;138:968-75
Suzuki T (*see* Tamai et al). 1999;138:968-75
Swales JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood Pressure Elevation-Regional and Global) project. 1999;138:S231-S237
Swedberg K (*see* O'Connor et al). 1999;138:78-86

T

Tada H (*see* Hongo et al). 1999;138:345-50
Taddeucci E (*see* Antoniucci et al). 1999;138:670-4
Taher M (*see* McAlister et al). 1999;138:87-94
Takahashi M (*see* Ueda et al). 1999;138:908-15
Takase S (*see* Tamai et al). 1999;138:968-75
Tamaguchi T (*see* Sakatani et al). 1999;138:962-7
Tamai H, Katoh O, Suzuki S, Fujii K, Aizawa T, Takase S, Kurogane H, Nishikawa H, Sone T, Sakai K, Suzuki T. Impact of tranilast on restenosis after coronary angioplasty: tranilast Restenosis following Angioplasty Trial (TREAT). 1999;138:968-75
Tannenbaum AK (*see* Khaw et al). 1999;138:934-40
Taqi K (*see* Ferguson and Taqi). 1999;138:S164-S170
Tarasoutchi F, Grinberg M, Filho JP, Izaki M, Cardoso LF, Pomerantezeff P, Nuschbacher A, da luz PL. Symptoms, left ventricular function, and timing of valve replacement surgery in patients with aortic regurgitation. 1999;138:477-85
Tateo IM (*see* Bello et al). 1999;138:100-7
Tavazzi L (*see* Fresco et al). 1999;138:1058-64
Tavazzi L. Clinical epidemiology of acute myocardial infarction. 1999;138:S48-S54
Taylor AJ (*see* Sangiorgi et al). 1999;138:681-7
Tcheng JE (*see* Pracyk et al). 1999;138:1014-5
Tcheng JE, Kong DF. Vale, warfarin: A stentorian farewell. 1999; 138:602-5 (Editorial)
Tcheng JE, Kereiakes DJ, Braden GA, Jordan RE, Mascelli MA, Langrall MA, Effron MB. Readministration of abciximab: interim report of the ReoPro Readministration Registry. 1999;138:S33-S38
Tcheng JE (*see* Gilchrist et al). 1999;138:976-82
Tcheng JE. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. 1999;138:S261-S262
Teatman LA (*see* Son et al). 1999;138:358-63
Tebbe U, Graf A, Kamke W, Zahn R, Foryski F, Kratzsch G, Berg G. Hemodynamic effects of double bolus reteplase ersus alteplase infusion in massive pulmonary embolism. 1999;138S39-S44
Teerlink JR, Massie BM. The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers. 1999;138:193-7
Teitelbaum F (*see* Roe et al). 1999;138:818-25
Teo KK (*see* McAlister et al). 1999;138:87-94
Teo KK, Catellier DJ. Long-term nitrate use in chronic coronary artery disease: need for a randomized controlled trial. 1999;138:400-2
Tepe NA (*see* Redle et al). 1999;138:144-50
Terheggen G (*see* Hoepp et al). 1999;138:941-9
Thomas JD (*see* Klein et al). 1999;138:880-9
Thomas N (*see* White et al). 1999;138:540-8
Thompson TD (*see* Hasdai et al). 1999;138:21-31
Thomssen R (*see* Suedkamp et al). 1999;138:269-72
Tilley AH, Stiles GL. To train or not to train. 1999;138:390-1 (Editorial)
Titus BG (*see* Fung et al). 1999;138:696-704
Tobis JM (*see* Son et al). 1999;138:358-63
Tognonia G (*see* Fresco et al). 1999;138:1058-64
Topol EJ (*see* Gilchrist et al). 1999;138:976-82
Topol EJ (*see* Mahaffey et al). 1999;138;493-9
Topol EJ (*see* Hasdai et al). 1999;138:21-31
Topol EJ (*see* Asher et al). 1999;138:1073-81
Topol EJ. Introduction. 1999;138:S561-S562
Toselli T (*see* Ferrari et al). 1999;138:S61-S68
Tousoulis D, Rallidis L, Cokkinos P, Davies G, Nihoyannopoulos P. Relation between exercise and dobutamine stress-induced wall motion abnormalities and severity and location of stenosis in single-vessel coronary artery disease. 1999;138:873-9
Trapani M (*see* Antoniucci et al). 1999;138:670-4
Trapani M (*see* Antoniucci et al). 1999;138:S147-S152
Trento A (*see* Khan et al). 1999;138:108-13
Triposkiadis F (*see* Hatzizacharias et al). 1999;138:241-6
Triposkiadis FK (*see* Makris et al). 1999;138:922-5
Tritto I (*see* Ambrosio and Tritto). 1999;138:S69-S75
Tummala RV (*see* Cooklin et al). 1999;138:133-6
Turner RC (*see* Adler et al). 1999;138:S353-S359
Twidale N, Manda V, Holliday R, Boler S, Sparks L, Crain J, Carrier S. Mitral regurgitation after atrioventricular node catheter ablation for atrial fibrillation and heart failure: acute hemodynamic features. 1999;138:1166-75
Tyroler J (*see* Beck et al). 1999;138:S529-S533

U

Ueda K, Takahashi M, Ozawa K, Kinoshita M. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction. 1999;138:908-15
Uemura A, Morimoto SI, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. 1999;138:299-302
Ungerleider RM. Biplane and multiplane transesophageal echocardiography. 1999;138:612-13
Upson B (*see* Garg et al). 1999;138:1082-7
Urbina EM, Gidding SS, Bao W, Elkasabany A, Berenson GS. Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study. 1999;138:122-7
Uretsky BF (*see* O'Connor et al). 1999;138:78-86

V

Vaccarino V, Chen YT, Wang Y, Radord MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. 1999;138:835-42
Vaghetti M (*see* Briguori et al). 1999;138:64-8
Vale PR (*see* Losordo et al). 1999;138:S132-S141
Valenti R (*see* Antoniucci et al). 1999;138:670-4
Valenti R (*see* Antoniucci et al). 1999;138:S147-S152
Valtonen VV. Role of infections in atherosclerosis. 1999;138: S431-S433
Van den Brand M (*see* Moons et al). 1999;138:525-32
Van Es GA (*see* Moons et al). 1999;138:525-32
Van Rossum AC (*see* Götte et al). 1999;138:1038-45
Van de Werf F. What do new lytics add to t-PA? 1999;138:S115-S120
Van Praagh R (*see* Pessotto et al). 1999;138:1184-95
Velazquez EJ, O'Connor CM. Heart failure after myocardial infarction: a good heart is hard to find. 1999;138:1009-11
Verheugt FWA (*see* Spiecker et al). 1999;138:518-24

Verma PK (*see* Kalra et al). 1999;138:339-44
Vermeer F (*see* Spiecker et al). 1999;138:518-24
Verrier RL (*see* Pope et al). 1999;138:890-9
Vesely DL, Dietz JR, Parks JR, Antwi EA, Overton RM, McCormick MT, Cintron G, Schocken DD. Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. 1999;138:625-32
Vicario MLE (*see* Bonaduce et al). 1999;138:273-84
Vidhun R (*see* Dangas et al). 1999;138:49-54
Vidhun R (*see* Dangas et al). 1999;138:49-54
Villegas M (*see* Pope et al). 1999;138:890-9
Virmani R (*see* Sangiorgi et al). 1999;138:681-7
Visser CA (*see* Götte et al). 1999;138:1038-45
Volpe M (*see* Bonaduce et al). 1999;138:273-84
Vom Dahl J (*see* Spiecker et al). 1999;138:518-24
Von Fisenne MJM (*see* Spiecker et al). 1999;138:518-24
Von Dryander S (*see* Machraoui et al). 1999;138:663-9
Voyatzi P (*see* Hatzizacharias et al). 1999;138:241-6

W

Wagner GS (*see* Pettis et al). 1999;138:765-70
Wahi S (*see* Klein et al). 1999;138:880-9
Walden J (*see* Lucas et al). 1999;138:618-24
Wali AU (*see* Hochman et al). 1999;138:313-8
Walter JD (*see* Will et al). 1999;138:1033-7
Wang A, Ryan T, Kisslo KB, Bashore TM, Harrison JK. Assessing the severity of mitral stenosis: variability between noninvasive and invasive measurements in patients with symptomatic mitral valve stenosis. 1999;138:777-84
Wang Y (*see* Vaccarino et al). 1999;138:835-42
Warner Stevenson L (*see* Weinfeld et al). 1999;138:285-90
Warner Stevenson L (*see* Lucas et al). 1999;138:618-24
Watson DD (*see* Sias et al). 1999;138:206-9 (Editorial)
Weaver WD (*see* Fung et al). 1999;138:696-704
Weaver WD (*see* Mahaffey et al). 1999;138;493-9
Weilenmann D (*see* Brunner-La Rocca et al). 1999;138:654-62
Weinfeld MS, Chertow GM, Warner Stevenson L. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. 1999;138:285-90
Weintraub WS, Kosinski A, Culler S. Comparison of outcome after coronary angioplasty and coronary surgery for multivessel coronary artery disease in persons with diabetes. 1999;138:S394-S399
Weiss AT (*see* Rozenman et al). 1999;138:441-5
Wener LS (*see* Son et al). 1999;138:358-63
Werdmann M (*see* Qamar et al). 1999;138:705-9
Werner M (*see* Pescatello et al). 1999;138:916-21
Westerhof PW (*see* Spiecker et al). 1999;138:518-24
Westveer DC (*see* Redle et al). 1999;138:144-50
Whelton PK (*see* He and Whelton). 1999;138:S211-S219
White AD, Rosamond WD, Chambless LE, Thomas N, Conwill D, Cooper LS, Folsom AR. Sex and race differences in short-term prognosis after acute coronary heart disease events: the Atherosclerosis Risk in Communities (ARIC) study. 1999;138:540-8
White CJ (*see* Silva et al). 1999;138:446-55
White HD. Newer antiplatelet agents in acute coronary syndromes. 1999;138:S570-S576
White HD (*see* Mahaffey et al). 1999;138;493-9
White HD. Optimal treatment of patients with acute coronary syndromes and non–ST-elevation myocardial infarction. 1999;138:S105-S114
White RD (*see* Klein et al). 1999;138:880-9
White WD (*see* Hochrein et al). 1999;138:791-7
Whitlow PL (*see* Hlatky et al). 1999;138:376-83
Wick G, Perchinka H, Xu Q. Autoimmunity and atherosclerosis. 1999;138:S444-S449
Wiens RD (*see* Hlatky et al). 1999;138:376-83
Wilensky RL, Pyles JM, Fineberg N. Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase. 1999;138:319-25
Wilkinson J (*see* Janorkar et al). 1999;138:1176-83
Wilkinson WE (*see* Pritchett and Wilkinson). 1999;138:994-7
Will PM, Walter JD. Exercise testing: improving performance with a ramped Bruce protocol. 1999;138:1033-7
Wilson AC (*see* Gregory et al). 1999;138:507-17
Windeler J (*see* Spiecker et al). 1999;138:518-24
Winston C (*see* Hlatky et al). 1999;138:376-83
Wolfe WG (*see* Hochrein et al). 1999;138:791-7
Wolpers H-G (*see* Blessing et al). 1999;138:1199 (Letter reply)
Wood MA (*see* Melton et al). 1999;138:1016-8
Wu JJ (*see* Hung et al). 1999;138:114-21
Wulbrecht N (*see* Ali et al). 1999;138:1133-9

X

Xu Q (*see* Wick et al). 1999;138:S444-S449

Y

Yamada E (*see* Pasquet et al). 1999;138:753-8
Yamada K (*see* Morimoto et al). 1999;138:456-9
Yamagishi M (*see* Hongo et al). 1999;138:345-50
Yap YG (*see* Aytemir and Yap). 1999;138:385 (Letter)
Yasick D (*see* Qamar et al). 1999;138:705-9
Yasumura Y (*see* Hongo et al). 1999;138:345-50
Yim R (*see* McAlister et al). 1999;138:87-94
Yonezawa K (*see* Nanbu et al). 1999;138:641-5
Yoshida I (*see* Sato et al). 1999;138:560-6
Yotsukura A (*see* Sato et al). 1999;138:560-6
Youssoub JJ (*see* Leprince et al). 1999;138:586-92
Yunis C (*see* Flack et al). 1999;138:856-64

Z

Zafrir N, Fink G, Klainman E, Sulkes J, Spitzer S. Relation between aerobic capacity and extent of myocardial ischemia in patients with normal cardiac function. 1999;138:1088-92
Zahka KG (*see* Siwik et al). 1999;138:771-6
Zahn R, Schiele R, Seidl K, Schuster S, Hauptmann KE, Voigtländer T, Gottwik M, Berg G, Kunz T, Glunz HG, Limbourg P, Senges J. Daytime and nighttime differences in patterns of performance of primary angioplasty in the treatment of patients with acute myocardial infarction. 1999;138:1111-7
Zahn R (*see* Tebbe et al). 1999;138:S39-S44
Zannad F (*see* O'Connor et al). 1999;138:78-86
Zarich S (*see* Qamar et al). 1999;138:705-9
Zellner C (*see* Stahl et al). 1999;138:1200 (Letter)
Zeltser D (*see* Kassirer et al). 1999;138:555-9
Zeng C, Zhu Z, Hu W. The People's Republic of China. 1999;138:1197 (Letter reply)
Zhang D-J (*see* Brunham and Zhang). 1999;138:S519-S522
Zhang S (*see* Silva et al). 1999;138:446-55
Zhou YF (*see* Epstein et al). 1999;138:S476-S478
Zhu J (*see* Epstein et al). 1999;138:S476-S478
Zhu Z. (*see* Zeng et al). 1999;138:1197 (Letter reply)
Zidar JP (*see* Batchelor and Zidar). 1999;138:203-5

Subject index*

A

Abciximab
- Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention (Dangas et al). 1999;138:49-54
- Potential non-glycoprotein IIb/IIIa effects of abciximab (Coller). 1999;138:S1-S5
- Readministration of abciximab: interim report of the ReoPro Readministration Registry (Tcheng et al). 1999;138:S33-S38

Adolescence
- Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study (Flack et al). 1999;138:486-92
- Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study (Urbina et al). 1999;138:122-7
- Long-term invasive and noninvasive results of percutaneous balloon pulmonary valvuloplasty in children, adolescents, and adults (Jarrar et al). 1999;138:950-4

Aged
- Effect of exercise training on heart rate variability in healthy older adults (Stein et al). 1999;138:567-76
- Elderly patients at highest risk with acute myocardial infarction are more frequently transferred from community hospitals to tertiary centers: reality or myth? (Mehta et al). 1999;138:688-95
- Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction (Jollis et al). 1999;138:S376-S380
- Sex differences in the clinical care and outcomes of congestive heart failure in the elderly (Vaccarino et al). 1999;138:835-42
- Systematic primary angioplasty in octogenarian and older patients (Antoniucci et al). 1999;138:670-4

Age factors
- Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects (Schlaich et al). 1999;138:810-17
- Systematic primary angioplasty in octogenarian and older patients (Antoniucci et al). 1999;138:670-4
- Transcatheter closure of patent ductus arteriosus with the use of Rashkind occluders and/or Gianturco coils: long-term follow-up in 123 patients and special reference to comparison, residual shunts, complications, and techniques (Janorkar and Wilkinson). 1999;138:1176-83

Alcohol consumption
- Lack of effect of recent alcohol consumption on the course of acute myocardial infarction (Mukamal et al). 1999;138:926-33

American College of Cardiology
- Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999 (Alexander et al). 1999;138:175-90

Angina pectoris
- Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging (Schroeder et al). 1999;138:731-9
- Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry (Scirica et al). 1999;138:1065-72

Angioplasty, balloon
- Practice still makes perfect (Jollis). 1999;138:394-5 (Editorial)

Angioplasty, transluminal percutaneous coronary
- Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty (Hlatky et al). 1999;138:376-83
- Comparison of outcome after coronary angioplasty and coronary surgery for multivessel coronary artery disease in persons with diabetes (Weintraub et al). 1999;138:S394-S399
- Current role of stenting in acute myocardial infarction (Antoniucci et al). 1999;138:S147-S152
- Daytime and nighttime differences in patterns of performance of primary angioplasty in the treatment of patients with acute myocardial infarction (Zahn et al). 1999;138:1111-7
- Do new devices add to the results of PTCA in acute myocardial infarction? (Moses and Moussa). 1999;138:S158-S163
- Hemostasis of the femoral vasculature: shouldn't we have an answer by now? (Pracyk et al). 1999;138:1014-5 (Editorial)
- Histopathology of postpercutaneous transluminal coronary angioplasty remodeling in human coronary arteries (Sangiorgi et al). 1999;138:681-7
- Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT) (Tamai et al). 1999;138:968-75
- Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase (Wilensky et al). 1999;138:319-25
- Patients with diabetes did better with coronary bypass graft surgery than with percutaneous transluminal coronary angioplasty: was this BARI finding real? (Kelsey). 1999;138:S387-S393
- Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization (Nash et al). 1999;138:422-9
- Primary intervention in acute myocardial infarction: do bankers' hours suffice, or should we invest our resources elsewhere? (Ajluni and O'Neill). 1999;138:1012-3 (Editorial)
- Primary PTCA versus thrombolytic therapy: an evidence-based summary (Ryan et al). 1999;138:S96-S104
- Systematic primary angioplasty in octogenarian and older patients (Antoniucci et al). 1999;138:670-4

Angiotensin-converting enzyme inhibitors
- Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure (Roe et al). 1999;138:818-25
- Aspirin worsens excercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors (Guazzi et al). 1999;138:254-60
- Concern for azotemia with angiotensin-converting enzyme inhibitors: public health implications and clinical relevance (Bart). 1999;138:801-3 (Editorial)
- How to use ACE-inhibitors, β-blockers, and new therapies in AMI (Maggioni and Latini). 1999;138:S183-S187
- The interaction of ACE inhibitors and aspirin in heart failure:

*July, part 1, pp. 1-190; part 2, pp. S1-S46; August, part 1, pp. 191-386; part 2, pp. S47-S202; September, part 1, pp. 387-592; part 2, pp. S203-S260; October, part 1, pp. 593-800; part 2, pp. S261-S326; November, part 1, pp. 801-1000, S327-S416; part 2, pp. S417-S560; December, part 1, pp. 1001-1200; part 2, pp. S561-S594.

Angiotensin-converting enzyme inhibitors—cont'd

torn between two lovers (Teerlink and Massie). 1999; 138:193-7 (Editorial)
Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data (Brooks et al). 1999;138:S246-S251
Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD) (Knight et al). 1999;138:849-55
Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects (Schlaich et al). 1999;138:810-17
Safety and efficacy of eprosartan, a new angiotensin II receptor blocker (Shusterman). 1999;138:S238-S245
Tailored treatment for heart failure: an emerging concept (Poole-Wilson). 1999;138:1005-6 (Editorial)
Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy (Murdoch et al). 1999;138:1126-32

Aorta

Natural history of early aortic paraprosthetic regurgitation: a five-year follow-up (Rallidis et al). 1999;138:351-7
Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy (Stern et al). 1999;138:746-52

Arrhythmias

Effect of dofetilide on survival in patients with supraventricular arrhythmias (Pritchett and Wilkinson). 1999;138:994-7

Aspirin

Alternate-day dosing of aspirin in atrial fibrillation (Posada and Barriales). 1999;138:137-43
Alternate-day dosing of aspirin in atrial fibrillation: a critical evaluation (Howes and Ezekowitz). 1999;138:13 (Editorial)
Aspirin worsens excercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors (Guazzi et al). 1999;138:254-60
Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study (Machraoui et al). 1999;138:663-9
The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers (Teerlink and Massie). 1999;138: 193-7 (Editorial)

Atherosclerosis

Animal models of *chlamydia* and atherosclerosis (Muhlestein). 1999;138:S514-S515
Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens (Fabricant and Fabricant). 1999; 138:S465-S468
Atherosclerosis is an inflammatory disease (Ross). 1999;138: S419-S420
Atherosclerotic disease in non–insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies (Orloff et al). 1999;138:S406-S412
Autoimmunity and atherosclerosis (Wick et al). 1999;138: S444-S449
Chlamydia pneumoniae and atherosclerosis: links to the disease process (Byrne and Kalayoglu). 1999;138:S488-S490
Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease (Gupta). 1999;138:S539-S541
Conclusions (Plotkin). 1999;138:S560
Coronary artery disease after heart transplantation and its relation to cytomegalovirus (Hosenpud). 1999;138:S469-S472
Coronary heart disease, *Helicobacter pylori*, dental disease, *Chlamydia pneumoniae*, and cytomegalovirus: meta-analyses of prospective studies (Danesh). 1999;138:S434-S437
Cytomegalovirus is involved in vascular pathology (Bruggeman). 1999;138:S473-S475
Cytomegalovirus vaccine (Plotkin). 1999;138:S484-S487
Dental infections and atherosclerosis (Beck et al). 1999;138: S528-S533
Design of future intervention studies for *Chlamydia pneumoniae* in atherosclerosis (Grayston). 1999;138:S556-S557
Designing studies to confirm a link between viral infection and atherosclerosis (Hodinka). 1999;138:S554-S555
Diet and atherosclerosis (Kritchevsky). 1999;138:S426-S430
Emerging role of antibiotics in atherosclerosis (Gurfinkel and Bozovich). 1999;138:S537-S538
Enteroviruses and myocardial infarction (Roivainen). 1999; 138:S479-S483
Epidemiology of *Chlamydia pneumoniae* in atherosclerosis (Saikku). 1999;138:S500-S503
Fulfillment of Koch's postulates and the causes of atherosclerosis (O'Connor). 1999;138:S550-S551
Functionality of specific immunity in atherosclerosis (Nicoletti et al). 1999;138:S438-S443
Helicobacter and atherosclerosis (Kusters and Kuipers). 1999; 138:S523-S527
How to design studies to confirm a link between bacterial infection and atherosclerosis (Campbell). 1999;138:S552-S553
How to design vaccination trials to prevent atherosclerosis (Capron). 1999;138:S558-S559
Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis (Kassirer et al). 1999; 138:555-9
Infection and atherosclerosis (Dodet and Plotkin). 1999;138: S417-S418
Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes (Asher et al). 1999;138:1073-81
Interaction of *Chlamydia pneumoniae* infection with other risk factors of atherosclerosis (Leinonen and Saikku). 1999;138:S504-S506
In vitro infection and pathogenesis of *Chlamydia pneumoniae* in endovascular cells (Quinn and Gaydos). 1999;138: S507-S511
Molecular biology of *Chlamydia pneumoniae* surface proteins and their role in immunopathogenicity (Christiansen et al). 1999;138:S491-S495
Molecular mediators of arterial inflammation: a role for microbial products? (Kol and Libby). 1999;138:S450-S452
Mouse models of *Chlamydia pneumoniae* infection and atherosclerosis (Campbell and Kuo). 1999;138:S516-S518
Multiple infections in carotid atherosclerotic plaques (Chiu). 1999;138:S534-S536
Pathologic manifestation of *chlamydial* infection (Kuo). 1999; 138:S496-S499
Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis (Epstein et al). 1999;138:S476-SS478
Role of infections in atherosclerosis (Valtonen). 1999;138:S431-S433
Secondary prevention trials for coronary artery disease with antibiotic treatment for *Chlamydia pneumoniae*: design issues (Grayston et al). 1999;138:S545-S549
Sex and race differences in short-term prognosis after acute coronary heart disease events: the Atherosclerosis Risk in Communities (ARIC) study (White et al). 1999; 138:540-9
Stable versus unstable atherosclerosis: clinical aspects (Falk). 1999;138:S421-S425

Atherosclerosis—cont'd

Transgene as vaccine for *chlamydia* (Brunham and Zhang). 1999;138:S519-S522
Value of animal models for *Chlamydia pneumoniae*-related atherosclerosis (Fong). 1999;138:S512-S513
Viral activation of the coagulation cascade (Nicholson and Hajjar). 1999;138:S461-S464
Viruses and atherosclerosis: a critical review of the epidemiologic evidence (Nieto). 1999;138:S453-S460
WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics (Dunne). 1999;138:S542-S544

Atrial fibrillation

Alternate-day dosing of aspirin in atrial fibrillation (Posada and Barriales). 1999;138:137-43
Alternate-day dosing of aspirin in atrial fibrillation: a critical evaluation (Howes and Ezekowitz). 1999;138:13 (Editorial)
Mitral regurgitation after atrioventricular node catheter ablation for atrial fibrillation and heart failure: acute hemodynamic features (Twidale et al). 1999;138:1166-75
Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery (Redle et al). 1999;138:144-50
Radiofrequency atrioventricular junction ablation for atrial fibrillation: how can we make it better? (Melton et al). 1999;138:1016-8 (Editorial)
Reduced risk for thromboembolism in atrial fibrillation and mitral regurgitation (Cheng) (Letter); (Yamamoto et al) (Reply). 1999;138:998

Atrial septal defects

ASDOS closures: congratulations and technical observations (O'Laughlin and Harrison). 1999;138:808-9 (Editorial)
Transcatheter closure of atrial-septal defects and patent foramen ovale in adults: optimal anatomic adaptation of occlusion device (Hoepp et al). 1999;138:941-9

B

Balloon dilatation

Complications of Inoue balloon mitral commissurotomy: impact of operator experience and evolving technique (Hung et al). 1999;138:114-21
Direct coronary stenting without balloon predilation in acute coronary syndromes (Hamon et al). 1999;138:55-9

Bedside monitoring

Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis (Corbalán et al). 1999;138:533-9
A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction (Katz et al). 1999;138:32-8

β-blockers

β-Blocker withdrawal: the song of Orpheus (Eichhorn). 1999;138:387-9 (Editorial)
Can β-blocker therapy be withdrawn from patients with dilated cardiomyopathy? (Morimoto et al). 1999;138:456-9
How to use ACE-inhibitors, β-blockers, and new therapies in AMI (Maggioni and Latini). 1999;138:S183-S187

Biopsies, endomyocardial

Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies (Uemura et al). 1999;138:299-302

Bleeding

Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors (Blankenship). 1999;138:S287-S296
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy (Juran). 1999;138:S297-S306

Blood flow velocity

Effect of distal stenosis of internal thoracic artery bypass grafts on longitudinal phasic blood flow velocity characteristics (Koyama et al). 1999;138:468-76

Blood pressure

Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas? (Carruthers). 1999;138:S256-S260
Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood Pressure Elevation—Regional and Global) project (Swales). 1999;138:S231-S237
Dynamic exercise normalizes resting blood pressure in mildly hypertensive premenopausal women (Pescatello et al). 1999;138:916-21
Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials (He and Whelton). 1999;138:S211-S219
Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile (Kannel). 1999;138:S205-S210
Influence of arterial pulse and reflected waves on blood pressure and cardiac function (London and Guerin). 1999;138:S220-S224
Integrated approaches to management of hypertension: promoting treatment acceptance (McInnes). 1999;138:S252-S255
Introduction: Challenging the paradigm for treatment of hypertension: focus on elevated systolic blood pressure (Julius and Brunner). 1999;138:S203-S204
Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data (Brooks et al). 1999;138:S246-S251
Risk reduction associated with lowering systolic blood pressure: review of clinical trial data (Hall). 1999;138:S225-S230
Safety and efficacy of eprosartan, a new angiotensin II reeceptor blocker (Shusterman). 1999;138:S238-S245
Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study (Flack et al). 1999;138:856-64

C

Cardiogenic shock

Cardiogenic shock complicating acute myocardial infarction: predictors of death (Hasdai et al). 1999;138:21-31
Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction (Santoro and Buonamici). 1999;138:S126-131

Cardiomyopathy, dilated

β-Blocker withdrawal: the song of Orpheus (Eichhorn). 1999;138:387-9 (Editorial)
Can β-blocker therapy be withdrawn from patients with dilated cardiomyopathy? (Morimoto et al). 1999;138:456-9
Cardiac myocytes of hearts from patients with end-stage dilated cardiomyopathy do not contain *Borrelia burgdorferi* DNA (Suedkamp et al). 1999;138:269-72
Lyme disease: an active agent in dilated cardiomyopathy? (Cuffe). 1999;138:198-9 (Editorial)
Myocardial high-energy phosphate metabolism in patients with stable chronic dilated cardiomyopathy under a dobutamine-induced prolonged mild workload (Nanbu et al). 1999;138:641-5

Cerebrovascular disorders

Preventing perioperative stroke: look, but don't touch! (Rakowski and Pearlman). 1999;138:609-11 (Editorial)
Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy (Stern et al). 1999;138:746-52

Child
Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study (Urbina et al). 1999;138:122-7
Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation (Calabrò et al). 1999;138:955-61
Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy (Lewis). 1999;138:334-8
Long-term invasive and noninvasive results of percutaneous balloon pulmonary valvuloplasty in children, adolescents, and adults (Jarrar et al). 1999;138:950-4

Clinical trials
Alternate-day dosing of aspirin in atrial fibrillation (Posada and Barriales). 1999;138:137-43
Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study (Flack et al). 1999;138:486-92
ARCTIC: *A*ssessment of haemodynamic *R*esponse in patients with *C*ongestive heart failure to *T*elmisartan: a multicentre dose-ranging study *I*n *C*anada (Parker et al). 1999;138:843-8
Complications of Inoue balloon mitral commissurotomy: impact of operator experience and evolving technique (Hung et al). 1999;138:114-21
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) (O'Connor et al). 1999;138:78-86
Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial (Moons et al). 1999;138:525-32
Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood Pressure Elevation—Regional and Global) project (Swales). 1999;138:S231-S237
Design of future intervention studies for *Chlamydia pneumoniae* in atherosclerosis (Grayston). 1999;138:S556-S557
Designing studies to confirm a link between viral infection and atherosclerosis (Hodinka). 1999;138:S554-S555
Development of eptifibatide (Scarborough). 1999;138:1093-1104
Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials (He and Whelton). 1999;138:S211-S219
Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials (Califf). 1999;138:S12-S15
How to design studies to confirm a link between bacterial infection and atherosclerosis (Campbell). 1999;138:S552-S553
How to design vaccination trials to prevent atherosclerosis (Capron). 1999;138:S558-S559
Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47) (Adler et al). 1999;138:S353-S359
Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT) (Tamai et al). 1999;138:968-75
Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial (Oliva et al). 1999;138:247-53
Long-term nitrate use in chronic coronary artery disease: need for a dandomized controlled trial (Teo and Catellier). 1999;138:400-2 (Editorial)
Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies (Nakamura et al). 1999;138:577-85
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the Sibrafiban versus aspirin to Yield Maximum Protection from Ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) Trial (Newby). 1999;138:210-18
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I Trial (Mahaffey et al). 1999;138:493-9
Newer antiplatelet agents in acute coronary syndromes (White). 1999;138:S570-S576
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes (Harrington). 1999;138:S276-S286
Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial (Goff Jr et al). 1999;138:1046-57
Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation (Lee et al). 1999;138:60-3
Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry (Scirica et al). 1999;138:1065-72
Randomized comparison of hemostasis techniques after invasive cardiovascular procedures (Lehmann et al). 1999;138:1118-25
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. Ecadotril Pilot Safety Study (O'Connor et al). 1999;138:1140-8
Risk reduction associated with lowering systolic blood pressure: review of clinical trial data (Hall). 1999;138:S225-S230
Secondary prevention trials for coronary artery disease with antibiotic treatment for *Chlamydia pneumoniae*: design issues (Grayston et al). 1999;138:S545-S549
Sex and race differences in short-term prognosis after acute coronary heart disease events: the Atherosclerosis Risk in Communities (ARIC) study (White et al). 1999;138:540-9
Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study (Flack et al). 1999;138:856-64
Statin trials and goals of cholesterol-lowering therapy after AMI (Pedersen). 1999;138:S177-S182
Straddling tricuspid valve as a sign of ventriculoatrial malalignment: a morphometric study of 19 postmortem cases (Pessotto et al). 1999;138:1184-95
Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial (Spiecker et al). 1999;138:518-24
Vale, warfarin: a stentorian farewell (Tcheng and Kong). 1999;138:602-5 (Editorial)
WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics (Dunne). 1999;138:S542-S544

Coronary angiography
Augmentation of vessel squeezing at coronary-myocardial bridge by nitroglycerin: study by quantitative coronary angiography and intravascular ultrasound (Hongo et al). 1999;138:345-50
Long-term angiographic results of stenting in chronic total occlusions: influence of stent design and vessel size (Escaned et al). 1999;138:675-80

Coronary artery bypass surgery
Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty (Hlatky et al). 1999;138:376-83
Coronary artery stent outcomes in a Medicare population: less emergency bypass surgery and lower mortality rates in patients with stents (Ritchie et al). 1999;138:437-40
Effect of clinical factors on length of stay after coronary artery

Coronary artery bypass surgery—cont'd

bypass surgery: results of the Cooperative Cardiovascular Project (Rosen et al). 1999;138:69-77
Mortality and the need for reoperation in patients with mild-to-moderate asymptomatic aortic valve disease undergoing coronary artery bypass graft alone (Hochrein et al). 1999;138:791-7
Multivessel coronary artery bypass surgery without cardiopulmonary bypass (Ardehali et al). 1999;138:983-6
Patients with diabetes did better with coronary bypass graft surgery than with percutaneous transluminal coronary angioplasty: was this BARI finding real? (Kelsey). 1999;138:S387-S393
Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery (Redle et al). 1999;138:144-50

Coronary disease

Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis (Corbalán et al). 1999;138:533-9
Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors (Blankenship). 1999;138:S287-S296
Comparison of the Diamond-Forrester method and a new score to estimate the pretest probability of coronary disease before exercise testing (Morise). 1999;138:740-5
Comparison of past versus recent physical activity in the prevention of premature death and coronary artery disease (Sherman et al). 1999;138:900-7
Coronary artery disease after heart transplantation and its relation to cytomegalovirus (Hosenpud). 1999;138:S469-S472
Coronary heart disease, *Helicobacter pylori*, dental disease, *Chlamydia pneumoniae*, and cytomegalovirus: meta-analyses of prospective studies (Danesh). 1999;138:S434-S437
C-reactive protein and coronary disease (Cremonini et al) (Letter); (Danchin et al) (Reply). 1999;138:999
Effects of endurance exercise training on left ventricular systolic performance and ventriculoarterial coupling in patients with coronary artery disease (Rinder et al). 1999;138:169-74
Histopathology of postpercutaneous transluminal coronary angioplasty remodeling in human coronary arteries (Sangiorgi et al). 1999;138:681-7
Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis (Kassirer et al). 1999;138:555-9
Long-term nitrate use in chronic coronary artery disease: need for a dandomized controlled trial (Teo and Catellier). 1999;138:400-2 (Editorial)
Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies (Nakamura et al). 1999;138:577-85
Long-term outcome of patients with very long stents for treatment of diffuse coronary disease (Rozenman et al). 1999;138:441-5
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy (Juran). 1999;138:S297-S306
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes (Harrington). 1999;138:S276-S286
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors (Kleiman). 1999;138:S263-S275
Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization (Dangas and Colombo). 1999;138:S16-S23
Relation between exercise and dobutamine stress-induced wall motion abnormalities and severity and location of stenosis in single-vessel coronary artery disease (Tousoulis et al). 1999;138:873-9
Risk stratifying acute coronary syndromes: gradient of risk and benefit (Hamm). 1999;138:S6-S11
Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective (Dyke). 1999;138:S307-S316
Sex and race differences in short-term prognosis after acute coronary heart disease events: the Atherosclerosis Risk in Communities (ARIC) study (White et al). 1999;138:540-9
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes (Tcheng). 1999;138:S261-S262
Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors (Madan and Berkowitz). 1999;138:S317-S326

Coronary disease, diagnosis

Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging (Schroeder et al). 1999;138:731-9

Coronary disease, treatment

The emerging role of low-molecular-weight heparin in the cardiac catheterization lab (Deutsch). 1999;138:S577-S585
Introduction (Topol). 1999;138:S561-S562
Newer antiplatelet agents in acute coronary syndromes (White). 1999;138:S570-S576
Newer antithrombin agents in acute coronary syndromes (Antman and Cohen). 1999;138:S563-S569
Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation? (Califf and Holmes Jr). 1999;138:S586-S594

Correction

Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Study III (NHANES III) (Herrington et al) (1998;136:115-24). 1999;138:798

Cost-benefit analysis

Assessing the cost of a cardiology residency program with a cost construction model (Franzini et al). 1999;138:414-21
Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty (Hlatky et al). 1999;138:376-83
Cost-effectiveness of reperfusion strategies (Parmley). 1999;138:S142-S146
Economic issues in glycoprotein Iib/IIIa receptor therapy (Hillegass et al). 1999;138:S24-S32
Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison (Cooper et al). 1999;138:430-6
To train or not to train (Tilley and Stiles). 1999;138:390-1 (Editorial)
Transradial cardiac catheterization: is femoral access obsolete? (Rihal and Holmes, Jr). 1999;138:392-3 (Editorial)

Costs and cost analysis

Costs and cost-effectiveness of routine transesophageal echocardiography in congenital heart surgery (Siwik et al). 1999;138:771-6

C-reactive protein

C-reactive protein and coronary disease (Cremonini et al) (Letter); (Danchin et al) (Reply). 1999;138:999

Curriculum in cardiology

Clinical features of Wolff-Parkinson-White syndrome (Al-Khatib and Pritchett). 1999;138:403-13
Constrictive pericarditis: clinical and pathophysiologic characteristics (Myers and Spodick). 1999;138:219-32

Cytomegalovirus
Coronary artery disease after heart transplantation and its relation to cytomegalovirus (Hosenpud). 1999;138:S469-S472
Cytomegalovirus is involved in vascular pathology (Bruggeman). 1999;138:S473-S475
Cytomegalovirus vaccine (Plotkin). 1999;138:S484-S487
Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis (Epstein et al). 1999;138:S476-SS478

D

Death
Cardiogenic shock complicating acute myocardial infarction: predictors of death (Hasdai et al). 1999;138:21-31
Comparison of past versus recent physical activity in the prevention of premature death and coronary artery disease (Sherman et al). 1999;138:900-7
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) (O'Connor et al). 1999;138:78-86
Relation betxween myocardial infarction, depression, hostility, and death (Kaufmann et al). 1999;138:549-54
Therapy of type 2 diabetes, cardiovascular death, and the UGDP (Feinglos and Bethel). 1999;138:S346-S352
Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction (Carinci et al). 1999;138:1058-64
Dental factors
Coronary heart disease, *Helicobacter pylori*, dental disease, *Chlamydia pneumoniae*, and cytomegalovirus: meta-analyses of prospective studies (Danesh). 1999;138:S434-S437
Dental infections and atherosclerosis (Beck et al). 1999;138:S528-S533
Depression
Relation between myocardial infarction, depression, hostility, and death (Kaufmann et al). 1999;138:549-54
Diabetes mellitus
Atherosclerotic disease in non–insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies (Orloff et al). 1999;138:S406-S412
Comparison of outcome after coronary angioplasty and coronary surgery for multivessel coronary artery disease in persons with diabetes (Weintraub et al). 1999;138:S394-S399
Diabetes and acute myocardial infarction: the role of insulin therapy (Malmberg and McGuire). 1999;138:S381-S386
Diabetes and ischemic heart disease (McGuire and Granger). 1999;138:S366-S375
FDA approach to the regulation of drugs for diabetes (Fleming). 1999;138:S338-S345
Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47) (Adler et al). 1999;138:S353-S359
Hypertension and diabetes: current issues (Furberg). 1999;138:S400-S405
Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus (Kang et al). 1999;138:1025-32
Insulin resistance syndrome and cardiovascular disease: genetics and connections to skeletal muscle function (Kraus). 1999;138:S413-S416
Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans Affairs (VA CSDM) feasibility trial (Abraira and McGuire). 1999;138:S360-S365
Introduction: proceedings of a symposium: diabetes and cardiovascular disease: current opinions and future directions (McGuire and Califf). 1999;138:S327-S329
Patients with diabetes did better with coronary bypass graft surgery than with percutaneous transluminal coronary angioplasty: was this BARI finding real? (Kelsey). 1999;138:S387-S393
Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome (Silva et al). 1999;138:446-55
Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction (Jollis et al). 1999;138:S376-S380
Therapy of type 2 diabetes, cardiovascular death, and the UGDP (Feinglos and Bethel). 1999;138:S346-S352
Treatment of diabetes mellitus: implications of the use of oral agents (Rao et al). 1999;138:S334-S337
Type 2 diabetes and macrovascular disease: epidemiology and etiology (Clark Jr and Perry). 1999;138:S330-S334
Diagnostic imaging
Comparison of the Diamond-Forrester method and a new score to estimate the pretest probability of coronary disease before exercise testing (Morise). 1999;138:740-5
Correlation between clinical and Doppler echocardiographic findings in patients with moderate and large pericardial effusion: implications for the diagnosis of cardiac tamponade (Mercé et al). 1999;138:759-64
Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients (Mankad et al). 1999;138:721-30
Improved endocardial visualization with second harmonic imaging compared with fundamental two-dimensional echocardiographic imaging (Senior et al). 1999;138:163-8
Influence of dobutamine or exercise stress on the results of pulsed-wave Doppler assessment of myocardial velocity (Pasquet et al). 1999;138:753-8
Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging (Schroeder et al). 1999;138:731-9
Relation between exercise and dobutamine stress-induced wall motion abnormalities and severity and location of stenosis in single-vessel coronary artery disease (Tousoulis et al). 1999;138:873-9
Second harmonic imaging: good reverberations (Crouse and Kramer). 1999;138:19-20 (Editorial)
Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study (Flack et al). 1999;138:856-64
Diastole
Diastolic potentials in verapamil-sensitive ventricular tachycardia: true potentials or bystanders of the reentry circuits? (Sato et al). 1999;138:560-6
Effects of long-term adrenergic β-blockade on left ventricular diastolic filling in patients with acute myocardial infarction (Poulsen et al). 1999;138:710-20
Old and new paradigms on diastolic function in acute myocardial infarction (Popovic). 1999;138:S84-S88
Role of transesophageal echocardiography in assessing diastolic dysfunction in a large clinical practice: a 9-year experience (Klein et al). 1999;138:880-9
Diet
Diet and atherosclerosis (Kritchevsky). 1999;138:S426-S430
Dobutamine
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart

Dobutamine—cont'd

failure: insights from the Flolan International Randomized Survival Trial (FIRST) (O'Connor et al). 1999;138:78-86
Influence of dobutamine or exercise stress on the results of pulsed-wave Doppler assessment of myocardial velocity (Pasquet et al). 1999;138:753-8
Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial (Oliva et al). 1999; 138:247-53
Myocardial high-energy phosphate metabolism in patients with stable chronic dilated cardiomyopathy under a dobutamine-induced prolonged mild workload (Nanbu et al). 1999;138:641-5
Preserved diagnostic utility of dobutamine stress echocardiography in pacemaker-dependent patients with absolute chronotropic incompetence (Oral et al). 1999;138:365-8
Relation between exercise and dobutamine stress-induced wall motion abnormalities and severity and location of stenosis in single-vessel coronary artery disease (Tousoulis et al). 1999;138:873-9

Dofetilide
Effect of dofetilide on survival in patients with supraventricular arrhythmias (Pritchett and Wilkinson). 1999;138:994-7

Drug therapy
ARCTIC: *A*ssessment of haemodynamic *R*esponse in patients with *C*ongestive heart failure to *T*elmisartan: a multicentre dose-ranging study *I*n *C*anada (Parker et al). 1999;138:843-8
Atherosclerotic disease in non–insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies (Orloff et al). 1999;138:S406-S412
Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study (Machraoui et al). 1999;138:663-9
Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia (Civeira et al). 1999;138:156-62
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure (Northridge et al). 1999;138:1149-57
Development of eptifibatide (Scarborough). 1999;138:1093-1104
Diastolic potentials in verapamil-sensitive ventricular tachycardia: true potentials or bystanders of the reentry circuits? (Sato et al). 1999;138:560-6
Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infaction (Fung et al). 1999;138:696-704
FDA approach to the regulation of drugs for diabetes (Fleming). 1999;138:S338-S345
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism (Tebbe et al). 1999;138:39-44
Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans Affairs (VA CSDM) feasibility trial (Abraira and McGuire). 1999;138:S360-S365
Is there still a future for neutral endopeptidase inhibitors? (Francis). 1999;138:1007-8 (Editorial)
Natriuretic peptides for treatment of congestive heart failure (DeNofrio). 1999;138:597-8 (Editorial)
Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? (Sias et al). 1999; 138:206-9 (Editorial)
Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies (Nakamura et al). 1999;138:577-85
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders (Murdock et al). 1999;138:151-5
Niacin treatment increases plasma homocyst(e)ine levels (Garg et al). 1999;138:1082-7
Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data (Brooks et al). 1999;138:S246-S251
Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery (Redle et al). 1999;138:144-50
Pulmonary embolism thrombolysis: do we need another agent? (Goldhaber). 1999;138:1-2 (Editorial)
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. Ecadotril Pilot Safety Study (O'Connor et al). 1999;138:1140-8
Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction (Jollis et al). 1999;138:S376-S380
Safety and efficacy of eprosartan, a new angiotensin II reeceptor blocker (Shusterman). 1999;138:S238-S245
Treatment of diabetes mellitus: implications of the use of oral agents (Rao et al). 1999;138:S334
Treatment of type III hyperlipoproteinemia (Guyton). 1999;138: 17-18 (Editorial)
Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure (Brunner-La Rocca et al). 1999;138:654-62

E

Echocardiography
Correlation between clinical and Doppler echocardiographic findings in patients with moderate and large pericardial effusion: implications for the diagnosis of cardiac tamponade (Mercé et al). 1999;138:759-64
Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients (Mankad et al). 1999;138:721-30
Improved endocardial visualization with second harmonic imaging compared with fundamental two-dimensional echocardiographic imaging (Senior et al). 1999;138:163-8
Influence of dobutamine or exercise stress on the results of pulsed-wave Doppler assessment of myocardial velocity (Pasquet et al). 1999;138:753-8
Preserved diagnostic utility of dobutamine stress echocardiography in pacemaker-dependent patients with absolute chronotropic incompetence (Oral et al). 1999; 138:365-8
Second harmonic imaging: good reverberations (Crouse and Kramer). 1999;138:19-20 (Editorial)

Echocardiography, transesophageal
Biplant and multiplane transesophageal echocardiography (Ungerleider). 1999;138:612-13 (Editorial)
Costs and cost-effectiveness of routine transesophageal echocardiography in congenital heart surgery (Siwik et al). 1999;138:771-6
Role of transesophageal echocardiography in assessing diastolic dysfunction in a large clinical practice: a 9-year experience (Klein et al). 1999;138:880-9

Editorials
Editorials. 1999;138:1-2, 3-4, 5-8, 9-12, 13, 14-16, 17-18, 19-20, 191-2, 193-7, 198-9, 200-2, 203-5, 206-9, 387-9, 390-1, 392-3, 394-5, 396-9, 400-2, 593-6, 597-8, 599-601, 602-5, 606-8, 609-11, 612-3, 614-7, 801-3, 804-7, 808-9, 1001-2, 1003-4, 1005-6, 1007-8, 1009-11, 1012-3, 1014-5, 1016-8

Electrocardiography
Evaluation of the efficacy of hand-held computer screens for cardiologists' interpretations of 12-lead electrocardiograms (Pettis et al). 1999;138:765-70

Electrocardiography—cont'd

Improved detection of posterior myocardial wall ischemia with the 15-lead electrocardiogram (Khaw et al). 1999;138:934-40

Electrophysiology

Alternate-day dosing of aspirin in atrial fibrillation (Posada and Barriales). 1999;138:137-43

Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation (Cooklin et al). 1999;138:133-6

Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia (Civeira et al). 1999;138:156-62

Diastolic potentials in verapamil-sensitive ventricular tachycardia: true potentials or bystanders of the reentry circuits? (Sato et al). 1999;138:560-6

Effect of dofetilide on survival in patients with supraventricular arrhythmias (Pritchett and Wilkinson). 1999;138:994-7

Effect of exercise training on heart rate variability in healthy older adults (Stein et al). 1999;138:567-76

Electrophysiologic procedures and activation of the hemostatic system (Michelucci et al). 1999;138:128-32

Persistent T-wave changes after radiofrequency catheter ablation of an accessory connection (Wolff-Parkinson-White syndrome) are caused by "cardiac memory" (Geller et al). 1999;138:987-93

Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery (Redle et al). 1999;138:144-50

Embolism

Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism (Tebbe et al). 1999;138:39-44

Pulmonary embolism thrombolysis: do we need another agent? (Goldhaber). 1999;138:1-2 (Editorial)

Enalapril

Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation (Calabrò et al). 1999;138:955-61

Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure (Brunner-La Rocca et al). 1999;138:654-62

Environment

First steps toward understanding the pathophysiologic link between air pollution and cardiac mortality (Stone and Godleski). 1999;138:804-7 (Editorial)

Heart rate variability associated with particulate air pollution (Pope et al). 1999;138:890-9

Eptifibatide

Development of eptifibatide (Scarborough). 1999;138:1093-1104

Exercise

Aspirin worsens excercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors (Guazzi et al). 1999;138:254-60

Comparison of past versus recent physical activity in the prevention of premature death and coronary artery disease (Sherman et al). 1999;138:900-7

Dynamic exercise normalizes resting blood pressure in mildly hypertensive premenopausal women (Pescatello et al). 1999;138:916-21

Effects of exercise training on chronotropic incompetence in patients with heart failure (Keteyian et al). 1999;138:233-40

A shuttle walk test for assessment of functional capacity in chronic heart failure (Morales et al). 1999;138:292-8

Exercise test

Comparison of the Diamond-Forrester method and a new score to estimate the pretest probability of coronary disease before exercise testing (Morise). 1999;138:740-5

Exercise testing: improving performance with a ramped Bruce protocol (Will and Walter). 1999;138:1033-7

Influence of dobutamine or exercise stress on the results of pulsed-wave Doppler assessment of myocardial velocity (Pasquet et al). 1999;138:753-8

Relation between exercise and dobutamine stress-induced wall motion abnormalities and severity and location of stenosis in single-vessel coronary artery disease (Tousoulis et al). 1999;138:873-9

Stress testing: national patterns and predictors of test ordering (Cohen et al). 1999;138:1019-24

Exercise tolerance

Determining prognosis in congestive heart failure: role of the 6-minute walk test (Bittner). 1999;138:593-6 (Editorial)

Effects of endurance exercise training on left ventricular systolic performance and ventriculoarterial coupling in patients with coronary artery disease (Rinder et al). 1999;138:169-74

Effect of exercise training on heart rate variability in healthy older adults (Stein et al). 1999;138:567-76

Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging (Schroeder et al). 1999;138:731-9

Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol (Guazzi et al). 1999;138:460-7

Relation between aerobic capacity and extent of myocardial schemia in patients with normal cardiac function (Zafrir et al). 1999;138:1088-92

The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival (Lucas et al). 1999;138:618-24

F

Fibrinolytic therapy

Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction (Ferrario et al). 1999;138:S121-S125

What do new lytics add to t-PA? (Van de Werf). 1999;138:S115-S120

Follow-up studies

Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study (Machraoui et al). 1999;138:663-9

Continued expansion of the nitinol self-expanding coronary stent: angiographic analysis and 1-year clinical follow-up (Roguin et al). 1999;138:326-33

Natural history of early aortic paraprosthetic regurgitation: a five-year follow-up (Rallidis et al). 1999;138:351-7

Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization (Nash et al). 1999;138:422-9

Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol (Guazzi et al). 1999;138:460-7

Transcatheter closure of patent ductus arteriosus with the use of Rashkind occluders and/or Gianturco coils: long-term follow-up in 123 patients and special reference to comparison, residual shunts, complications, and techniques (Janorkar and Wilkinson). 1999;138:1176-83

Transcatheter device closure of ventricular septal defects:

Follow-up studies—cont'd

immediate results and intermediate-term follow-up (Kalra et al). 1999;138:339-44

G

Gemfibrozil
Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia (Civeira et al). 1999;138:156-62
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders (Murdock et al). 1999;138:151-5

Genes
Gene therapy for myocardial angiogenesis (Losordo et al). 1999;138:S132-S141
Insulin resistance syndrome and cardiovascular disease: genetics and connections to skeletal muscle function (Kraus). 1999;138:S413-S416

H

Health policy
Assessing the cost of a cardiology residency program with a cost construction model (Franzini et al). 1999;138:414-21
Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors (Blankenship). 1999;138:S287-S296
Effect of clinical factors on length of stay after coronary artery bypass surgery: results of the Cooperative Cardiovascular Project (Rosen et al). 1999;138:69-77
Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison (Cooper et al). 1999;138:430-6
Impact of availability of hospital-based invasive cardiac services on racial differences in the use of these services (Gregory et al). 1999;138:507-17
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy (Juran). 1999;138:S297-S306
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes (Harrington). 1999;138:S276-S286
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors (Kleiman). 1999;138:S263-S275
Racial differences in the use of invasive cardiac procedures: a continuous quality improvement approach (Sheifer and Schulman). 1999;138:396-9 (Editorial)
To train or not to train (Tilley and Stiles). 1999;138:390-1 (Editorial)
Translation of clinical evidence into medical practice (Anstrom and Jollis). 1999;138:1001-2 (Editorial)
Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective (Dyke). 1999;138:S307-S316
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes (Tcheng). 1999;138:S261-S262
Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors (Madan and Berkowitz). 1999;138:S317-S326

Heart defects, congenital
Actual failure rates: a method of assessing tissue valve reoperation rates (Khan et al). 1999;138:108-13
Costs and cost-effectiveness of routine transesophageal echocardiography in congenital heart surgery (Siwik et al). 1999;138:771-6
Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation (Calabrò et al). 1999;138:955-61
Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy (Lewis). 1999;138:334-8

Heart failure
Aggravated renal dysfunction and the acute management of advanced chronic heart failure (Bart and Goldsmith). 1999;138:200-2 (Editorial)
Clinical predictors of heart failure in patients with first acute myocardial infarction (Ali et al). 1999;138:1133-9
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure (Northridge et al). 1999;138:1149-57
Contemporary issues in heart failure (Ghali). 1999;138:5-8 (Editorial)
Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction (Goldstein et al). 1999;138:1158-65
Heart failure after myocardial infarction: a good heart is hard to find (Velazques and O'Connor). 1999;138:1009-11 (Editorial)
Heart failure: a case for subspecialized care management (Smith and Konstam). 1999;138:14-16 (Editorial)
The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers (Teerlink and Massie). 1999;138:193-7 (Editorial)
Mitral regurgitation after atrioventricular node catheter ablation for atrial fibrillation and heart failure: acute hemodynamic features (Twidale et al). 1999;138:1166-75
Multidisciplinary interventions for the management of heart failure: where do we stand? (Rich). 1999;138:599-601 (Editorial)
Pandora's box is torn asunder (Jaffe). 1999;138:9-12 (Editorial)
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. Ecadotril Pilot Safety Study (O'Connor et al). 1999;138:1140-8
Relation between aerobic capacity and extent of myocardial schemia in patients with normal cardiac function (Zafrir et al). 1999;138:1088-92
Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure (Bello et al). 1999;138:100-7
Tailored treatment for heart failure: an emerging concept (Poole-Wilson). 1999;138:1005-6 (Editorial)
Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy (Murdoch et al). 1999;138:1126-32

Heart failure, congestive
Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure (Roe et al). 1999;138:818-25
ARCTIC: *A*ssessment of haemodynamic *R*esponse in patients with *C*ongestive heart failure to *T*elmisartan: a multicentre dose-ranging study *I*n *C*anada (Parker et al). 1999;138:843-8
Aspirin worsens excercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors (Guazzi et al). 1999;138:254-60
Cardiac myocytes of hearts from patients with end-stage dilated infarction (Ali et al). 1999;138:1133-9
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure (Northridge et al). 1999;138:1149-57
Contemporary issues in heart failure (Ghali). 1999;138:5-8 (Editorial)

Heart failure, congestive—cont'd

Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction (Goldstein et al). 1999;138:1158-65

Heart failure after myocardial infarction: a good heart is hard to find (Velazques and O'Connor). 1999;138:1009-11 (Editorial)

Heart failure: a case for subspecialized care management (Smith and Konstam). 1999;138:14-16 (Editorial)

The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers (Teerlink and Massie). 1999;138: 193-7 (Editorial)

Mitral regurgitation after atrioventricular node catheter ablation for atrial fibrillation and heart failure: acute hemodynamic features (Twidale et al). 1999;138:1166-75

Multidisciplinary interventions for the management of heart failure: where do we stand? (Rich). 1999;138:599-601 (Editorial)

Pandora's box is torn asunder (Jaffe). 1999;138:9-12 (Editorial)

A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. Ecadotril Pilot Safety Study (O'Connor et al). 1999;138:1140-8

Relation between aerobic capacity and extent of myocardial schemia in patients with normal cardiac function (Zafrir et al). 1999;138:1088-92

Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure (Bello et al). 1999;138:100-7

Tailored treatment for heart failure: an emerging concept (Poole-Wilson). 1999;138:1005-6 (Editorial)

Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy (Murdoch et al). 1999;138:1126-32

Heart failure, congestive, therapy

Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure (Roe et al). 1999;138: 818-25

ARCTIC: *A*ssessment of haemodynamic *R*esponse in patients with *C*ongestive heart failure to *T*elmisartan: a multicentre dose-ranging study *I*n *C*anada (Parker et al). 1999;138:843-8

Aspirin worsens excercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors (Guazzi et al). 1999;138:254-60

Cardiac myocytes of hearts from patients with end-stage dilated cardiomyopathy do not contain *Borrelia burgdorferi* DNA (Suedkamp et al). 1999;138:269-72

Cardiac troponins in congestive heart failure (Del Carlo and O'Connor). 1999;138:646-53

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST) (O'Connor et al). 1999;138:78-86

Determining prognosis in congestive heart failure: role of the 6-minute walk test (Bittner). 1999;138:593-6 (Editorial)

Effects of exercise training on chronotropic incompetence in patients with heart failure (Keteyian et al). 1999;138:233-40

Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies (Uemura et al). 1999;138:299-302

Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure (Bonaduce et al). 1999;138:273-84

Insights into the contemporary epidemiology and outpatient management of congestive heart failure (McAlister et al). 1999;138:87-94

Intermittent inotropes for advanced heart failure: inquiring minds want to know (Silver). 1999;138:191-2 (Editorial)

Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure (Hatzizacharias et al). 1999;138:241-6

Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial (Oliva et al). 1999;138: 247-53

A new regimen for heparin use in acute coronary syndromes (Hochman et al). 1999;138:313-18

Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD) (Knight et al). 1999;138:849-55

Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects (Schlaich et al). 1999;138:810-17

Sex differences in the clinical care and outcomes of congestive heart failure in the elderly (Vaccarino et al). 1999;138: 835-42

A shuttle walk test for assessment of functional capacity in chronic heart failure (Morales et al). 1999;138:292-8

The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival (Lucas et al). 1999;138:618-24

Variations in family physicians' and cardiologists' care for patients with heart failure (Baker et al). 1999;138:826-34

Ventricular remodeling in active myocarditis (Mendes et al). 1999;138:303-12

Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure (Brunner-La Rocca et al). 1999;138:654-62

Heart failure, congestive, drug therapy

Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure (Weinfeld et al). 1999;138: 285-91

Can β-blocker therapy be withdrawn from patients with dilated cardiomyopathy? (Morimoto et al). 1999;138:456-9

Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure (Vesely et al). 1999;138:625-32

Effect of a home monitoring system on hospitalization and resource use for patients with heart failure (Heidenreich et al). 1999;138:633-40

Myocardial high-energy phosphate metabolism in patients with stable chronic dilated cardiomyopathy under a dobutamine-induced prolonged mild workload (Nanbu et al). 1999;138:641-5

Natriuretic peptides for treatment of congestive heart failure (DeNofrio). 1999;138:597-8 (Editorial)

A novel biochemical approach to congestive heart failure: cardiac troponin T (Missov and Mair). 1999;138:95-9

Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol (Guazzi et al). 1999;138: 460-7

Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure (Kukin et al). 1999;138:261-8

Heart rate

Effect of exercise training on heart rate variability in healthy older adults (Stein et al). 1999;138:567-76

Heart rate variability associated with particulate air pollution (Pope et al). 1999;138:890-9

Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure (Bonaduce et al). 1999;138:273-84

A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction (Katz et al). 1999;138:32-8

Heart transplantation
Coronary artery disease after heart transplantation and its relation to cytomegalovirus (Hosenpud). 1999;138:S469-S472
Does use of intravascular ultrasound accelerate arteriopathy in heart transplant patients? (Son et al). 1999;138:358-64
Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients (Mankad et al). 1999;138:721-30
Posttransplantation cytotoxic immunoglobulin G is associated with a high rate of acute allograft dysfunctions in heart transplant recipients (Leprince et al). 1999;138:586-92
Hemodynamics
Exercise testing: improving performance with a ramped Bruce protocol (Will and Walter). 1999;138:1033-7
Intermittent inotropes for advanced heart failure: inquiring minds want to know (Silver). 1999;138:191-2 (Editorial)
Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure (Hatzizacharias et al). 1999;138:241-6
Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure (Kukin et al). 1999;138:261-8
Hemostasis
Randomized comparison of hemostasis techniques after invasive cardiovascular procedures (Lehmann et al). 1999;138:1118-25
Heparin
Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infaction (Fung et al). 1999;138:696-704
Electrophysiologic procedures and activation of the hemostatic system (Michelucci et al). 1999;138:128-32
The emerging role of low-molecular-weight heparin in the cardiac catheterization lab (Deutsch). 1999;138:S577-S585
A new regimen for heparin use in acute coronary syndromes (Hochman et al). 1999;138:313-18
Hospitalization
Effect of clinical factors on length of stay after coronary artery bypass surgery: results of the Cooperative Cardiovascular Project (Rosen et al). 1999;138:69-77
Effect of a home monitoring system on hospitalization and resource use for patients with heart failure (Heidenreich et al). 1999;138:633-40
Elderly patients at highest risk with acute myocardial infarction are more frequently transferred from community hospitals to tertiary centers: reality or myth? (Mehta et al). 1999;138:688-95
Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial (Goff Jr et al). 1999;138:1046-57
Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction (Carinci et al). 1999;138:1058-64
Hyperinsulinemia
Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study (Urbina et al). 1999;138:122-7
Hypertension
Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas? (Carruthers). 1999;138:S256-S260
Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study (Urbina et al). 1999;138:122-7
Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood Pressure Elevation—Regional and Global) project (Swales). 1999;138:S231-S237
Elevated plasma immunoreactive leptin levels preexist in healthy offspring of patients with essential hypertension (Makris et al). 1999;138:922-5
Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials (He and Whelton). 1999;138:S211-S219
Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile (Kannel). 1999;138:S205-S210
Hypertension and diabetes: current issues (Furberg). 1999;138:S400-S405
Influence of arterial pulse and reflected waves on blood pressure and cardiac function (London and Guerin). 1999;138:S220-S224
Integrated approaches to management of hypertension: promoting treatment acceptance (McInnes). 1999;138:S252-S255
Introduction: Challenging the paradigm for treatment of hypertension: focus on elevated systolic blood pressure (Julius and Brunner). 1999;138:S203-S204
Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data (Brooks et al). 1999;138:S246-S251
Pulmonary hypertension in patients with thalassemia major (Derchi et al) (Letter); (Du and Roguin) (Reply). 1999;138:384
Risk reduction associated with lowering systolic blood pressure: review of clinical trial data (Hall). 1999;138:S225-S230
Safety and efficacy of eprosartan, a new angiotensin II reeceptor blocker (Shusterman). 1999;138:S238

I

Image processing, computer assisted
Augmentation of vessel squeezing at coronary-myocardial bridge by nitroglycerin: study by quantitative coronary angiography and intravascular ultrasound (Hongo et al). 1999;138:345-50
Axial movement of the intravascular ultrasound probe during the cardiac cycle: implications for three-dimensional reconstruction and measurements of coronary dimensions (Arbab-Zadeh et al). 1999;138:865-72
Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus (Kang et al). 1999;138:1025-32
Nitrate-enhanced thallium 201 single-photon emission computed tomography imaging in hibernating myocardium (Oudiz et al). 1999;138:369-75
Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? (Sias et al). 1999;138:206-9 (Editorial)
Infection
Animal models of *chlamydia* and atherosclerosis (Muhlestein). 1999;138:S514-S515
Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens (Fabricant and Fabricant). 1999;138:S465-S468
Atherosclerosis is an inflammatory disease (Ross). 1999;138:S419-S420
Autoimmunity and atherosclerosis (Wick et al). 1999;138:S444-S449
Chlamydia pneumoniae and atherosclerosis: links to the disease process (Byrne and Kalayoglu). 1999;138:S488-S490
Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease (Gupta). 1999;138:S539-S541

Infection—cont'd

Conclusions (Plotkin). 1999;138:S560
Coronary artery disease after heart transplantation and its relation to cytomegalovirus (Hosenpud). 1999;138:S469-S472
Coronary heart disease, *Helicobacter pylori*, dental disease, *Chlamydia pneumoniae*, and cytomegalovirus: meta-analyses of prospective studies (Danesh). 1999;138:S434-S437
Cytomegalovirus is involved in vascular pathology (Bruggeman). 1999;138:S473-S475
Cytomegalovirus vaccine (Plotkin). 1999;138:S484-S487
Dental infections and atherosclerosis (Beck et al). 1999;138:S528-S533
Design of future intervention studies for *Chlamydia pneumoniae* in atherosclerosis (Grayston). 1999;138:S556-S557
Designing studies to confirm a link between viral infection and atherosclerosis (Hodinka). 1999;138:S554-S555
Diet and atherosclerosis (Kritchevsky). 1999;138:S426-S430
Emerging role of antibiotics in atherosclerosis (Gurfinkel and Bozovich). 1999;138:S537-S538
Enteroviruses and myocardial infarction (Roivainen). 1999;138:S479-S483
Epidemiology of *Chlamydia pneumoniae* in atherosclerosis (Saikku). 1999;138:S500-S503
Fulfillment of Koch's postulates and the causes of atherosclerosis (O'Connor). 1999;138:S550-S551
Functionality of specific immunity in atherosclerosis (Nicoletti et al). 1999;138:S438-S443
Helicobacter and atherosclerosis (Kusters and Kuipers). 1999;138:S523-S527
How to design studies to confirm a link between bacterial infection and atherosclerosis (Campbell). 1999;138:S552-S553
How to design vaccination trials to prevent atherosclerosis (Capron). 1999;138:S558-S559
Infection and atherosclerosis (Dodet and Plotkin). 1999;138:S417-S418
Interaction of *Chlamydia pneumoniae* infection with other risk factors of atherosclerosis (Leinonen and Saikku). 1999;138:S504-S506
In vitro infection and pathogenesis of *Chlamydia pneumoniae* in endovascular cells (Quinn and Gaydos). 1999;138:S507-S511
Molecular biology of *Chlamydia pneumoniae* surface proteins and their role in immunopathogenicity (Christiansen et al). 1999;138:S491-S495
Molecular mediators of arterial inflammation: a role for microbial products? (Kol and Libby). 1999;138:S450-S452
Mouse models of *Chlamydia pneumoniae* infection and atherosclerosis (Campbell and Kuo). 1999;138:S516-S518
Multiple infections in carotid atherosclerotic plaques (Chiu). 1999;138:S534-S536
Pathologic manifestation of *chlamydial* infection (Kuo). 1999;138:S496-S499
Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis (Epstein et al). 1999;138:S476-SS478
Role of infections in atherosclerosis (Valtonen). 1999;138:S431-S433
Secondary prevention trials for coronary artery disease with antibiotic treatment for *Chlamydia pneumoniae*: design issues (Grayston et al). 1999;138:S545-S549
Stable versus unstable atherosclerosis: clinical aspects (Falk). 1999;138:S421-S425
Transgene as vaccine for *chlamydia* (Brunham and Zhang). 1999;138:S519-S522
Value of animal models for *Chlamydia pneumoniae*-related atherosclerosis (Fong). 1999;138:S512-S513
Viral activation of the coagulation cascade (Nicholson and Hajjar). 1999;138:S461-S464
Viruses and atherosclerosis: a critical review of the epidemiologic evidence (Nieto). 1999;138:S453-S460
WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics (Dunne). 1999;138:S542-S544

Insulin

Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study (Urbina et al). 1999;138:122-7
Diabetes and acute myocardial infarction: the role of insulin therapy (Malmberg and McGuire). 1999;138:S381-S386
Insulin resistance syndrome and cardiovascular disease: genetics and connections to skeletal muscle function (Kraus). 1999;138:S413-S416
Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans Affairs (VA CSDM) feasibility trial (Abraira and McGuire). 1999;138:S360-S365

L

Language

Confusion in geography (Cheng) (Letter); (Sanderson) (Reply); (Zeng et al) (Reply). 1999;138:1196, 1196, 1196-7, 1197

Letters

Confusion in geography (Cheng) (Letter); (Sanderson) (Reply); (Zeng et al) (Reply). 1999;138:1196, 1196, 1196-7, 1197
C-reactive protein and coronary disease (Cremonini et al) (Letter); (Danchin et al) (Reply). 1999;138:999
Defining risk in unstable angina (Friedman) (Letter); (Bazzino) (Reply). 1999;138:1197-8, 1198
Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention (Ikeda et al) (Letter). 1999;138:1199-200
Effect of acute ischemia on QT dispersion (Aytemir et al) (Letter); (Somberg and Molnar) (Reply). 1999;138:385-386
Observer-related variability in IVUS measurements after stenting (Regar et al) (Letter); Blessing et al) (Reply). 1999;138:1198-9, 1199
Pulmonary hypertension in patients with thalassemia major (Derchi et al) (Letter); (Du and Roguin) (Reply). 1999;138:384
Reduced risk for thromboembolism in atrial fibrillation and mitral regurgitation (Cheng) (Letter); (Yamamoto et al) (Reply). 1999;138:998
Telemedicine in cardiology (Stahl et al) (Letter). 1999;138:1200

Lipoproteins, LDL cholesterol

Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia (Civeira et al). 1999;138:156-62
Treatment of type III hyperlipoproteinemia (Guyton). 1999;138:17-18 (Editorial)

Lyme disease

Cardiac myocytes of hearts from patients with end-stage dilated cardiomyopathy do not contain *Borrelia burgdorferi* DNA (Suedkamp et al). 1999;138:269-72
Lyme disease: an active agent in dilated cardiomyopathy? (Cuffe). 1999;138:198-9 (Editorial)

M

Managed care programs

Effect of clinical factors on length of stay after coronary artery bypass surgery: results of the Cooperative Cardiovascular Project (Rosen et al). 1999;138:69-77
Heart failure: a case for subspecialized care management (Smith and Konstam). 1999;138:14-16 (Editorial)

Managed care programs—cont'd

Self-reported differences between cardiologists and heart failure specialists in the management of chronic heart failure (Bello et al). 1999;138:100-7
Translation of clinical evidence into medical practice (Anstrom and Jollis). 1999;138:1001-2 (Editorial)

Medicare

Coronary artery stent outcomes in a Medicare population: less emergency bypass surgery and lower mortality rates in patients with stents (Ritchie et al). 1999;138:437-40

Metoprolol

Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction (Goldstein et al). 1999; 138:1158-65
Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure (Kukin et al). 1999;138: 261-8

Milrinone

Intermittent inotropes for advanced heart failure: inquiring minds want to know (Silver). 1999;138:191-2 (Editorial)
Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure (Hatzizacharias et al). 1999;138:241-6

Mitral valve insufficiency

Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study (Flack et al). 1999;138:486-92
Assessing the severity of mitral stenosis: variability between noninvasive and invasive measurements in patients with symptomatic mitral valve stenosis (Wang et al). 1999;138: 777-84
Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation (Calabrò et al). 1999;138:955-61
Mitral regurgitation after atrioventricular node catheter ablation for atrial fibrillation and heart failure: acute hemodynamic features (Twidale et al). 1999;138:1166-75
Reduced risk for thromboembolism in atrial fibrillation and mitral regurgitation (Cheng) (Letter); (Yamamoto et al) (Reply). 1999;138:998

Models

Animal models of *chlamydia* and atherosclerosis (Muhlestein). 1999;138:S514-S515
Assessing the cost of a cardiology residency program with a cost construction model (Franzini et al). 1999;138: 414-21
Mouse models of *Chlamydia pneumoniae* infection and atherosclerosis (Campbell and Kuo). 1999;138:S516-S518
Value of animal models for *Chlamydia pneumoniae*-related atherosclerosis (Fong). 1999;138:S512-S513

Mortality

Comparison of past versus recent physical activity in the prevention of premature death and coronary artery disease (Sherman et al). 1999;138:900-7
First steps toward understanding the pathophysiologic link between air pollution and cardiac mortality (Stone and Godleski). 1999;138:804-7 (Editorial)
Mortality and the need for reoperation in patients with mild-to-moderate asymptomatic aortic valve disease undergoing coronary artery bypass graft alone (Hochrein et al). 1999;138:791-7

Myocardial angiogenesis

Gene therapy for myocardial angiogenesis (Losordo et al). 1999;138:S132

Myocardial infarction

Advances in antithrombotic therapy of acute myocardial infarction (Gensini et al). 1999;138:S171-S176
Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis (Corbalán et al). 1999;138:533-9
Cardiac troponin I as a marker for AMI (Londbloom and Stevermer) (Letter); (Apple and Sharkey) (Reply). 1999; 138:798
Clinical epidemiology of acute myocardial infarction (Tavazzi). 1999;138:S48-S54
Clinical predictors of heart failure in patients with first acute myocardial infarction (Ali et al). 1999;138:1133-9
Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction (Bhatt et al). 1999;138:785-90
Cost-effectiveness of reperfusion strategies (Parmley). 1999; 138:S142-S146
Current role of stenting in acute myocardial infarction (Antoniucci et al). 1999;138:S147-S152
Daytime and nighttime differences in patterns of performance of primary angioplasty in the treatment of patients with acute myocardial infarction (Zahn et al). 1999;138: 1111-7
Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction (Ueda et al). 1999;138:908-15
Do new devices add to the results of PTCA in acute myocardial infarction? (Moses and Moussa). 1999;138:S158-S163
Early predictors of left ventricular remodeling after acute myocardial infarction (Bolognese and Cerisano). 1999;138: S79-S83
Elderly patients at highest risk with acute myocardial infarction are more frequently transferred from community hospitals to tertiary centers: reality or myth? (Mehta et al). 1999;138:688-95
Enteroviruses and myocardial infarction (Roivainen). 1999;138:S479-S483
Gene therapy for myocardial angiogenesis (Losordo et al). 1999;138:S132-S141
The Goldman algorithm revisited: prospective evaluation of a computer-derived algorithm versus unaided physician judgment in suspected acute myocardial infarction (Qamar et al). 1999;138:705-9
Heart failure after myocardial infarction: a good heart is hard to find (Velazques and O'Connor). 1999;138:1009-11 (Editorial)
How to use ACE-inhibitors, β-blockers, and new therapies in AMI (Maggioni and Latini). 1999;138:S183-S187
IIb/IIIa receptor blockade in acute myocardial infarction (Ferguson and Taqi). 1999;138:S164-S170
Improved detection of posterior myocardial wall ischemia with the 15-lead electrocardiogram (Khaw et al). 1999; 138:934-40
Introduction: The dawn of a new era in the treatment of acute myocardial infarction (Antoniucci et al). 1999;138:S47
Ischemic preconditioning, myocardial stunning, and hibernation: basic aspects (Ferrari et al). 1999;138:S61-S68
Lack of effect of recent alcohol consumption on the course of acute myocardial infarction (Mukamal et al). 1999;138: 926-33
Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction (Ferrario et al). 1999;138:S121-S125
Microvascular integrity after reperfusion therapy (Agati). 1999; 138:S76-S78
No time to wait (Borzak). 1999;138:1003-4 (Editorial)
Old and new paradigms on diastolic function in acute myocardial infarction (Popovic). 1999;138:S84-S88
Optimal management of acute myocardial infarction at the dawn of the next millennium (Gersh). 1999;138:S188-S202
Optimal treatment of patients with acute coronary syndromes and non–ST-elevation myocardial infarction (White). 1999; 138:S105-S114

Myocardial infarction—cont'd

From plaque biology to clinical setting (Arbustini et al). 1999; 138:S55-S60
Prehospital testing for troponin T in patients with suspected acute myocardial infarction (Schuchert et al). 1999;138:45-8
Primary intervention in acute myocardial infarction: do bankers' hours suffice, or should we invest our resources elsewhere? (Ajluni and O'Neill). 1999;138: 1012-3 (Editorial)
Primary PTCA versus thrombolytic therapy: an evidence-based summary (Ryan et al). 1999;138:S96-S104
Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome (Silva et al). 1999;138:446-55
Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction (Colombo and Briguori). 1999;138: S153-S157
Recanalization versus reperfusion for myocardial survival and preservation of ventricular geometry (L'Abbate). 1999;138: S89-S95
Recognition of infarct localization by specific changes in intramural myocardial mechanics (Götte et al). 1999;138:1038-45
Relation between aerobic capacity and extent of myocardial schemia in patients with normal cardiac function (Zafrir et al). 1999;138:1088-92
Relation between myocardial infarction, depression, hostility, and death (Kaufmann et al). 1999;138:549-54
Reperfusion injury: experimental evidence and clinical implications (Ambrosio and Tritto). 1999;138:S69-S75
Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction (Santoro and Buonamici). 1999;138: S126-131
Statin trials and goals of cholesterol-lowering therapy after AMI (Pedersen). 1999;138:S177-S182
Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction (Carinci et al). 1999;138:1058-64
What do new lytics add to t-PA? (Van de Werf). 1999;138: S115-S120)

Myocardial infarction, complications

Cardiogenic shock complicating acute myocardial infarction: predictors of death (Hasdai et al). 1999;138:21-31

Myocardial infarction, prevention and control

Cardiogenic shock complicating acute myocardial infarction: predictors of death (Hasdai et al). 1999;138:21-31
Optimal management of acute myocardial infarction at the dawn of the next millennium (Gersh). 1999;138:S188-S202
A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction (Katz et al). 1999;138:32-8

Myocardial infarction, therapy

Advances in antithrombotic therapy of acute myocardial infarction (Gensini et al). 1999;138:S171-S176
Diabetes and acute myocardial infarction: the role of insulin therapy (Malmberg and McGuire). 1999;138:S381-S386
Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infaction (Fung et al). 1999;138:696-704
Effects of long-term adrenergic β-blockade on left ventricular diastolic filling in patients with acute myocardial infarction (Poulsen et al). 1999;138:710-20
How to use ACE-inhibitors, β-blockers, and new therapies in AMI (Maggioni and Latini). 1999;138:S183-S187
IIb/IIIa receptor blockade in acute myocardial infarction (Ferguson and Taqi). 1999;138:S164-S170
Microvascular integrity after reperfusion therapy (Agati). 1999;138:S76-S78
Optimal management of acute myocardial infarction at the dawn of the next millennium (Gersh). 1999;138:S188-S202
Optimal treatment of patients with acute coronary syndromes and non–ST-elevation myocardial infarction (White). 1999;138:S105-S114
Primary PTCA versus thrombolytic therapy: an evidence-based summary (Ryan et al). 1999;138:S96-S104
Recanalization versus reperfusion for myocardial survival and preservation of ventricular geometry (L'Abbate). 1999; 138:S89-S95
Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction (Jollis et al). 1999;138:S376-S380
Statin trials and goals of cholesterol-lowering therapy after AMI (Pedersen). 1999;138:S177-S182
Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial (Spiecker et al). 1999;138:518-24
What do new lytics add to t-PA? (Van de Werf). 1999;138:S115-S120)

Myocardial ischemia

Diabetes and ischemic heart disease (McGuire and Granger). 1999;138:S366-S375
Effect of acute ischemia on QT dispersion (Aytemir et al) (Letter); (Somberg and Molnar) (Reply). 1999;138:385-386

Myocardial reperfusion

Cost-effectiveness of reperfusion strategies (Parmley). 1999;138:S142-S146
Microvascular integrity after reperfusion therapy (Agati). 1999;138:S76-S78
Recanalization versus reperfusion for myocardial survival and preservation of ventricular geometry (L'Abbate). 1999;138: S89-S95
Reperfusion injury: experimental evidence and clinical implications (Ambrosio and Tritto). 1999;138:S69-S75
Reperfusion therapy in cardiogenic shock complicating acute myocardial infarction (Santoro and Buonamici). 1999;138: S126-131

Myocarditis

Ventricular remodeling in active myocarditis (Mendes et al). 1999;138:303-12

N

Nitrates

Nitrate-enhanced thallium 201 single-photon emission computed tomography imaging in hibernating myocardium (Oudiz et al). 1999;138:369-75

Nitroglycerin

Augmentation of vessel squeezing at coronary-myocardial bridge by nitroglycerin: study by quantitative coronary angiography and intravascular ultrasound (Hongo et al). 1999;138:345-50
Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? (Sias et al). 1999; 138:206-9 (Editorial)

O

Outcome assessment

Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty (Hlatky et al). 1999;138:376-83
Clinical outcome after multivessel coronary stent implantation (Mathew et al). 1999;138:1105-10
Comparison of outcome after coronary angioplasty and

Outcome assessment—cont'd

coronary surgery for multivessel coronary artery disease in persons with diabetes (Weintraub et al). 1999;138: S394-S399
Complications of Inoue balloon mitral commissurotomy: impact of operator experience and evolving technique (Hung et al). 1999;138:114-21
Contemporary issues in heart failure (Ghali). 1999;138:5-8 (Editorial)
Coronary artery stent outcomes in a Medicare population: less emergency bypass surgery and lower mortality rates in patients with stents (Ritchie et al). 1999;138: 437-40
Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction (Bhatt et al). 1999;138:785-90
Effect of clinical factors on length of stay after coronary artery bypass surgery: results of the Cooperative Cardiovascular Project (Rosen et al). 1999;138:69-77
Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience (Gilchrist et al). 1999;138:976-82
Ethnicity and long-term outcome after an acute coronary event (Nakamura et al). 1999;138:500-6
Insights into the contemporary epidemiology and outpatient management of congestive heart failure (McAlister et al). 1999;138:87-94
Long-term angiographic results of stenting in chronic total occlusions: influence of stent design and vessel size (Escaned et al). 1999;138:675-80
Long-term outcome of patients with very long stents for treatment of diffuse coronary disease (Rozenman et al). 1999;138:441-5
Practice still makes perfect (Jollis). 1999;138:394-5 (Editorial)
Role of transesophageal echocardiography in assessing diastolic dysfunction in a large clinical practice: a 9-year experience (Klein et al). 1999;138:880-9
Sex differences in the clinical care and outcomes of congestive heart failure in the elderly (Vaccarino et al). 1999;138: 835-42
Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial (Spiecker et al). 1999;138:518-24

P

Pacemakers
Preserved diagnostic utility of dobutamine stress echocardiography in pacemaker-dependent patients with absolute chronotropic incompetence (Oral et al). 1999;138:365-8
Pain
Chest pain algorithms in the troponin era: time to integrate expertise (Lee). 1999;138:606-8 (Editorial)
Perfusion
Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? (Sias et al). 1999;138:206-9 (Editorial)
Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging (Schroeder et al). 1999;138:731-9
Pericarditis
Constrictive pericarditis: clinical and pathophysiologic characteristics (Myers and Spodick). 1999;138:219-32
Pharmaceutical industry
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors (Kleiman). 1999;138:S263-S275
Plasma
Elevated plasma immunoreactive leptin levels preexist in healthy offspring of patients with essential hypertension (Makris et al). 1999;138:922-5
Niacin treatment increases plasma homocyst(e)ine levels (Garg et al). 1999;138:1082-7
Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy (Murdoch et al). 1999;138:1126-32
Platelet membrane glycoproteins
Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors (Blankenship). 1999;138:S287-S296
Economic issues in glycoprotein IIb/IIIa receptor therapy (Hillegass et al). 1999;138:S24-S32
Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention (Dangas et al). 1999;138: 49-54
Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials (Califf). 1999;138:S12-S15
IIb/IIIa receptor blockade in acute myocardial infarction (Ferguson and Taqi). 1999;138:S164-S170
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the Sibrafiban versus aspirin to Yield Maximum Protection from Ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) Trial (Newby). 1999;138:210-18
Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction (Ferrario et al). 1999;138:S121-S125
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy (Juran). 1999;138:S297-S306
Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy? (Kereiakes). 1999;138:S39-46
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes (Harrington). 1999;138:S276-S286
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors (Kleiman). 1999;138:S263-S275
Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization (Dangas and Colombo). 1999;138: S16-S23
Potential non-glycoprotein IIb/IIIa effects of abciximab (Coller). 1999;138:S1-S5
Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction (Colombo and Briguori). 1999;138:S153-S157
Readministration of abciximab: interim report of the ReoPro Readministration Registry (Tcheng et al). 1999;138:S33-S38
Risk stratifying acute coronary syndromes: gradient of risk and benefit (Hamm). 1999;138:S6-S11
Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective (Dyke). 1999;138:S307-S316
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes (Tcheng). 1999;138:S261-S262
Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors (Madan and Berkowitz). 1999; 138:S317-S326
Protamine
Administration of protamine after coronary stent deployment (Briguori et al). 1999;138:64-8

Q

Quality of care
Effect of transradial access on quality of life and cost of cardiac catheterization: a randomized comparison (Cooper et al). 1999;138:430-6
Transradial cardiac catheterization: is femoral access obsolete? (Rihal and Holmes, Jr). 1999;138:392-3 (Editorial)
Variations in family physicians' and cardiologists' care for patients with heart failure (Baker et al). 1999;138:826-34

R

Racial factors
Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study (Flack et al). 1999;138:486-92
Impact of availability of hospital-based invasive cardiac services on racial differences in the use of these services (Gregory et al). 1999;138:507-17
Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes (Asher et al). 1999;138:1073-81
Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry (Scirica et al). 1999;138:1065-72
Racial differences in the use of invasive cardiac procedures: a continuous quality improvement approach (Sheifer and Schulman). 1999;138:396-9 (Editorial)
Sex and race differences in short-term prognosis after acute coronary heart disease events: the Atherosclerosis Risk in Communities (ARIC) study (White et al). 1999;138:540-9
Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study (Flack et al). 1999;138:856-64
Remodeling
Continued expansion of the nitinol self-expanding coronary stent: angiographic analysis and 1-year clinical follow-up (Roguin et al). 1999;138:326-33
Early predictors of left ventricular remodeling after acute myocardial infarction (Bolognese and Cerisano). 1999;138:S79-S83
Favorable vascular remodeling from self-expanding stents: magic or myth? (Batchelor and Zidar). 1999;138:203-5 (Editorial)
Histopathology of postpercutaneous transluminal coronary angioplasty remodeling in human coronary arteries (Sangiorgi et al). 1999;138:681-7
Ventricular remodeling in active myocarditis (Mendes et al). 1999;138:303-12
Renal disease and dysfunction
Aggravated renal dysfunction and the acute management of advanced chronic heart failure (Bart and Goldsmith). 1999;138:200-2 (Editorial)
Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure (Weinfeld et al). 1999;138:285-91
Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials (He and Whelton). 1999;138:S211-S219
Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD) (Knight et al). 1999;138:849-55
Reperfusion
Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction (Bhatt et al). 1999;138:785-90
Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction (Carinci et al). 1999;138:1058-64
Restenosis
Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT) (Tamai et al). 1999;138:968-75
Potential role of cytomegalovirus in the pathogenesis of restenosis and atherosclerosis (Epstein et al). 1999;138:S476-SS478
Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation (Lee et al). 1999;138:60-3
Steroids for restenosis: strike three! (Kong). 1999;138:3-4 (Editorial)

S

Sex factors
Sex differences in the clinical care and outcomes of congestive heart failure in the elderly (Vaccarino et al). 1999;138:835-42
Stents
Administration of protamine after coronary stent deployment (Briguori et al). 1999;138:64-8
Clinical outcome after multivessel coronary stent implantation (Mathew et al). 1999;138:1105-10
Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study (Machraoui et al). 1999;138:663-9
Continued expansion of the nitinol self-expanding coronary stent: angiographic analysis and 1-year clinical follow-up (Roguin et al). 1999;138:326-33
Coronary artery stent outcomes in a Medicare population: less emergency bypass surgery and lower mortality rates in patients with stents (Ritchie et al). 1999;138:437-40
Current role of stenting in acute myocardial infarction (Antoniucci et al). 1999;138:S147-S152
Direct coronary stenting without balloon predilation in acute coronary syndromes (Hamon et al). 1999;138:55-9
Favorable vascular remodeling from self-expanding stents: magic or myth? (Batchelor and Zidar). 1999;138:203-5 (Editorial)
Intracoronary surface changes after Palmaz-Schatz stent implantation: serial observations with coronary angioscopy (Sakatani et al). 1999;138:962-7
Long-term angiographic results of stenting in chronic total occlusions: influence of stent design and vessel size (Escaned et al). 1999;138:675-80
Long-term outcome of patients with very long stents for treatment of diffuse coronary disease (Rozenman et al). 1999;138:441-5
Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome (Silva et al). 1999;138:446-55
Primary stenting and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction (Colombo and Briguori). 1999;138:S153-S157
Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation (Lee et al). 1999;138:60-3
Steroids for restenosis: strike three! (Kong). 1999;138:3-4 (Editorial)
Stroke
Preventing perioperative stroke: look, but don't touch! (Rakowski and Pearlman). 1999;138:609-11 (Editorial)

Stroke—cont'd

Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy (Stern et al). 1999;138:746-52

T

Thallium
Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus (Kang et al). 1999;138:1025-32
Nitrate-enhanced thallium 201 single-photon emission computed tomography imaging in hibernating myocardium (Oudiz et al). 1999;138:369-75

Thrombin
Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention (Dangas et al). 1999;138:49-54
Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase (Wilensky et al). 1999;138:319-25
Newer antithrombin agents in acute coronary syndromes (Antman and Cohen). 1999;138:S563-S569

Thrombocytopenia
Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors (Madan and Berkowitz). 1999; 138:S317-S326

Thromboembolism
Electrophysiologic procedures and activation of the hemostatic system (Michelucci et al). 1999;138:128-32
Reduced risk for thromboembolism in atrial fibrillation and mitral regurgitation (Cheng) (Letter); (Yamamoto et al) (Reply). 1999;138:998

Thrombolysis in Myocardial Infarction Investigators
The sundial and the stopwatch (Gibson). 1999;138:614-17 (Editorial)

Thrombolytic therapy
Advances in antithrombotic therapy of acute myocardial infarction (Gensini et al). 1999;138:S171-S176
Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials (Califf). 1999;138:S12-S15
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism (Tebbe et al). 1999;138:39-44
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I Trial (Mahaffey et al). 1999;138: 493-9
Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial (Goff Jr et al). 1999;138:1046-57
Primary PTCA versus thrombolytic therapy: an evidence-based summary (Ryan et al). 1999;138:S96-S104
Pulmonary embolism thrombolysis: do we need another agent? (Goldhaber). 1999;138:1-2 (Editorial)
Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial (Spiecker et al). 1999;138:518-24

Troponin
Cardiac troponins in congestive heart failure (Del Carlo and O'Connor). 1999;138:646-53
Cardiac troponin I as a marker for AMI (Londbloom and Stevermer) (Letter); (Apple and Sharkey) (Reply). 1999; 138:798
Chest pain algorithms in the troponin era: time to integrate expertise (Lee). 1999;138:606-8 (Editorial)
A novel biochemical approach to congestive heart failure: cardiac troponin T (Missov and Mair). 1999;138:95-9
Pandora's box is torn asunder (Jaffe). 1999;138:9-12 (Editorial)
Prehospital testing for troponin T in patients with suspected acute myocardial infarction (Schuchert et al). 1999;138:45-8

U

Ultrasonography, interventional
Augmentation of vessel squeezing at coronary-myocardial bridge by nitroglycerin: study by quantitative coronary angiography and intravascular ultrasound (Hongo et al). 1999;138:345-50
Axial movement of the intravascular ultrasound probe during the cardiac cycle: implications for three-dimensional reconstruction and measurements of coronary dimensions (Arbab-Zadeh et al). 1999;138:865-72
Does use of intravascular ultrasound accelerate arteriopathy in heart transplant patients? (Son et al). 1999;138:358-64
Improved endocardial visualization with second harmonic imaging compared with fundamental two-dimensional echocardiographic imaging (Senior et al). 1999;138:163-8
Second harmonic imaging: good reverberations (Crouse and Kramer). 1999;138:19-20 (Editorial)

V

Valvular heart disease
Actual failure rates: a method of assessing tissue valve reoperation rates (Khan et al). 1999;138:108-13
Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study (Flack et al). 1999;138:486-92
Assessing the severity of mitral stenosis: variability between noninvasive and invasive measurements in patients with symptomatic mitral valve stenosis (Wang et al). 1999; 138:777-84
Corrected TIMI frame count does not predict 30-day adverse outcomes after reperfusion therapy for acute myocardial infarction (Bhatt et al). 1999;138:785-90
Effect of distal stenosis of internal thoracic artery bypass grafts on longitudinal phasic blood flow velocity characteristics (Koyama et al). 1999;138:468-76
Ethnicity and long-term outcome after an acute coronary event (Nakamura et al). 1999;138:500-6
Long-term invasive and noninvasive results of percutaneous balloon pulmonary valvuloplasty in children, adolescents, and adults (Jarrar et al). 1999;138:950-4
Mortality and the need for reoperation in patients with mild-to-moderate asymptomatic aortic valve disease undergoing coronary artery bypass graft alone (Hochrein et al). 1999;138:791-7
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I Trial (Mahaffey et al). 1999;138:493-9
Straddling tricuspid valve as a sign of ventriculoatrial malalignment: a morphometric study of 19 postmortem cases (Pessotto et al). 1999;138:1184-95
Symptoms, left ventricular function, and timing of valve replacement surgery in patients with aortic regurgitation (Tarasoutchi et al). 1999;138:477-85
Transcatheter closure of atrial-septal defects and patent fora-

Valvular heart disease—cont'd

men ovale in adults: optimal anatomic adaptation of occlusion device (Hoepp et al). 1999;138:941-9

Vasodilation

Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy (Murdoch et al). 1999;138:1126-32

Ventricular fibrillation

Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation (Cooklin et al). 1999;138:133-6

Ventricular function

Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy (Lewis). 1999;138:334-8

Transcatheter device closure of ventricular septal defects: immediate results and intermediate-term follow-up (Kalra et al). 1999;138:339-44

Ventricular function, left

Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial (Moons et al). 1999;138:525-32

Effects of endurance exercise training on left ventricular systolic performance and ventriculoarterial coupling in patients with coronary artery disease (Rinder et al). 1999;138:169-74

Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction (Goldstein et al). 1999;138:1158-65

Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects (Schlaich et al). 1999;138:810-17

Symptoms, left ventricular function, and timing of valve replacement surgery in patients with aortic regurgitation (Tarasoutchi et al).

Ventricular septal defects

Transcatheter device closure of ventricular septal defects: immediate results and intermediate-term follow-up (Kalra et al). 1999;138:339-44

W

Warfarin

Vale, warfarin: a stentorian farewell (Tcheng and Kong). 1999;138:602-5 (Editorial)

Wolff-Parkinson-White syndrome

Clinical features of Wolff-Parkinson-White syndrome (Al-Khatib and Pritchett). 1999;138:403-13

Persistent T-wave changes after radiofrequency catheter ablation of an accessory connection (Wolff-Parkinson-White syndrome) are caused by "cardiac memory" (Geller et al). 1999;138:987-93

Women

Dynamic exercise normalizes resting blood pressure in mildly hypertensive premenopausal women (Pescatello et al). 1999;138:916-21